Document:

EX-10.18

 Exhibit 10.18 

COLLABORATION AGREEMENT 

between 
 ABL Bio

 and 
 I-Mab 
 Dated July 26, 2018 

 This Collaboration Agreement (“Agreement”) is made and entered into as of the date first
written above (the “Effective Date”) by and between ABL Bio having a business address at ***, Republic of Korea (“ABL Bio”) and I-Mab, having a business address at ***
(“I-Mab ”). For purposes of this Agreement, ABL Bio and I-Mab are each referred to individually as a “Party” and together the
“Parties.” 
 WHEREAS, ABL Bio has developed expertise in the area of bi-specific antibodies for cancer treatment and has developed
proprietary intellectual property around the technology for BsAb (the “BsAb Technology” as further defined herein). 
 WHEREAS, I-Mab has developed three antibodies that it desires to incorporate into a bi-specific antibody using such BsAb Technology and has expertise in developing biologics. 

WHEREAS, ABL Bio and I-Mab agreed to collaborate to enable the development and commercialization of PD-L1/4-1BB, PD-L1/TIGIT and PD-L1/B7H3 BsAbs (each as defined herein); 

WHEREAS, ABL Bio and I-Mab entered into five Materials Transfer Agreements for the transfer of certain DNA and
protein sequences of applicable antibodies from I-Mab to ABL Bio (the “Materials Transfer Agreement”). 

NOW, THEREFORE, I-Mab and ABL Bio agree in this Collaboration Agreement (“Agreement”) as
follows: 
  

	1.	 Definitions 

 

	 	1.1	 “Affiliates” shall mean with respect to a Party, an entity that directly or indirectly through
one (1) or more intermediaries, controls, is controlled by or is under common control with such Party. In this definition, “control” means: (a) in the case of corporate entities, direct or indirect ownership of at least fifty
percent (50%) of the stock or shares having the right to vote for the election of directors; and (b) in the case of non-corporate entities, direct or indirect ownership of at least fifty percent (50%) of
the equity interest with the power to direct the management and policies of such entities. 

  

	 	1.2	 “ABL Bio Parental Antibody” shall mean the monoclonal antibody against 4-1BB and B7H3, controlled by ABL Bio as described in Appendix 1. 

  

	 	1.3	 “ABL Bio Parental Antibody Patent Rights” shall mean any and all Patent Rights
Controlled by ABL Bio during the Term that claim or cover the composition, use or manufacture of the Parental Antibodies. Such Patent Rights are listed in Appendix 1, as may be updated from time to time. 

 

	 	1.4	 “Business Day” shall mean any day (other than Saturday or Sunday) when banks are open for
business in both China and the Republic of Korea. 

  

	 	1.5	 “BsAb” shall mean a bi-specific antibody molecule
constructed by the combination of two Parental Antibodies using BsAb Technology, wherein one of the Parental Antibodies is PD-L1, and the other is TIGIT, 4-1BB or B7H3.

  

	 	1.6	 “BsAb Improvements” shall mean any and all improvements to the BsAb, whether patentable or
not, that have been identified, discovered or made by or on behalf of either Party or its Affiliates during the Term. For avoidance of doubt, any and all improvements to BsAb Technology, ABL Bio Parental Antibody and
I-Mab Parental Antibody that are specifically designed for BsAb should be deemed BsAb Improvements. 

  
 - 1 - 

	 	1.7	 “BsAb Technology” shall mean the Know-How Controlled
by ABL Bio during the Term that is reasonably necessary or useful for the practice of the bispecific antibody platform technology, which can cause one antibody to bind two different targeted antigens as described in Appendix 1.

  

	 	1.8	 “BsAb Technology Improvement(s)” shall mean any and all data, results and other Know-How, inventions and developments that constitute improvements to the BsAb Technology, whether patentable or not, that have been identified, discovered or made by or on behalf of either Party or its Affiliates
during the Term and are not specifically designed for BsAb. For the avoidance of doubt, Know-How and Patent Rights pertaining solely to the BsAb Technology itself (but not to Parental Antibody Technology)
shall be deemed as BsAb Technology Improvement, and any and all improvements to the BsAb Technology that are specifically designed for BsAb should be deemed BsAb. 

 

	 	1.9	 “Ca” shall mean the percentage value of costs sharing ascribed to ABL Bio in Appendix
5. 

  

	 	1.10	 “Ci” shall mean the percentage value of cost sharing ascribed to I-Mab in Appendix 5. 

  

	 	1.11	 “Clinical Development” shall mean the Research and Development after the fulfilment of
Decision Point II. 

  

	 	1.12	 “Clinical Development Plan” shall mean, subject to Section 3, a plan
for the Clinical Development activities to be performed by either Party under this Agreement that may be amended from time to time according to Section 6. 

 

	 	1.13	 “Clinical Development Report” shall mean, subject to Section 3, the
report provided by a Party to the other Party summarizing the Clinical Development activities it has performed during the past calendar quarter. 

  

	 	1.14	 “Clinical Study Completed” shall mean upon the completion of submission and acceptance of a
clinical study report (CSR) concerning the applicable clinical study phase. 

  

	 	1.15	 “Confidential Information” shall mean all information and data, of a confidential or
proprietary nature, which is obtained directly or indirectly by one Party (the “Receiving Party”) or its Affiliates, from the other Party (the “Disclosing Party”) or its Affiliates at any time before, on, or after
the Effective Date, without regard to the form or manner in which such information is disclosed or obtained (including information disclosed orally or in documentary or electronic form or by way of model, or obtained by observation). The existence
and terms of this Agreement are Confidential Information of both Parties. BsAb Technology, BsAb Technology Improvements, ABL Bio Parental Antibody Technology and ABL Bio Parental Antibody Improvements are the Confidential Information of ABL Bio, and
ABL Bio is deemed as the Disclosing Party with respect to all BsAb Technology, BsAb Technology Improvements, ABL Bio Parental Antibody Technology and ABL Bio Parental Antibody Improvements. I-Mab Parental
Antibody Technology and I-Mab Parental Antibody Improvements are the Confidential Information of I-Mab and I-Mab is deemed as the
Disclosing Party with respect to all I-Mab Parental Antibody Technology and I-Mab Parental Antibody Improvements. BsAb Improvements are the Confidential Information of
ABL Bio and I-Mab, and ABL Bio and I-Mab are deemed as the Disclosing Party with respect to all BsAb Improvements. 

 

	 	1.16	 “Commercially Reasonable Efforts” shall mean the efforts, time, costs and resources invested
that are comparable with the efforts, time, costs and resources a similarly situated pharmaceutical company would normally invest into a proprietary development candidate or pharmaceutical product of comparable nature, value and development stage.

  
 - 2 - 

	 	1.17	 “Control” or “Controlled” shall mean, with respect to an item or right, the
possession, whether by ownership or license (in each case other than pursuant to this Agreement), by a Party of the item or right, or the ability of a Party to grant to the other Party access to or a license to or under each such item or right as
provided in this Agreement without violating any agreement or other arrangement with any Third Party. 

  

	 	1.18	 “CRO” or “CMO” shall mean a company or other business entity providing
contract research services by performing research based on orders by customers. 

  

	 	1.19	 “Debar”, “Debarred” or “Debarment” shall mean
(a) being debarred, or being subject to a pending debarment, pursuant to section 306 of the FDCA, 21 U.S.C. § 335a or similar laws outside the United States, (b) being listed by any federal and/or state agencies, excluded, debarred,
suspended or otherwise made ineligible to participate in federal or state healthcare programs or federal procurement or non-procurement programs (as that term is defined in 42 U.S.C. 1320a-7b(f) or similar laws outside the United States), or being subject to any pending process by which any such listing, exclusion, debarment, suspension or other ineligibility could occur, (c) being
disqualified by any government or regulatory agency from performing specific services, or being subject to a pending disqualification proceeding, or (d) being convicted of a criminal offense related to the provision of healthcare items or
services or being subject to any pending criminal action related to the provision of healthcare items or services. 

  

	 	1.20	 “Decision Point” shall mean any of Decision Point I, Decision Point II, Decision Point III and
Decision Point IV. 

  

	 	1.21	 “Decision Point I” shall mean immediately after the completion of final candidate selection
via in vivo efficacy test according to study protocols approved by the JC. 

  

	 	1.22	 “Decision Point II” shall mean immediately after the submission of IND Application for Phase I
Clinical Study to the Food and Drug Administration in the U.S. 

  

	 	1.23	 “Decision Point III” shall mean immediately after Phase I Clinical Study Completed in the U.S.

  

	 	1.24	 “Decision Point IV” shall mean immediately after Phase II Clinical Study Completed in the U.S.

  

	 	1.25	 “Disclosing Party” shall have the meaning as described in
Section 1.15. 

  

	 	1.26	 “Early Development” shall mean the Research and Development prior to fulfilment of Decision
Point I. 

  

	 	1.27	 “Early Development Plan” shall mean a plan for the Early Development activities to be
performed by I-Mab and ABL Bio under this Agreement as attached to this Agreement as Appendix 3 that may be amended by approval of the JC. 

 

	 	1.28	 “Early Development Report” shall mean the report provided by a Party to the other Party
summarizing the Early Development activities it has performed during the past calendar quarter. 

  

	 	1.29	 “I-Mab Parental Antibody” shall mean the
monoclonal antibodies against PD-L1 and TIGIT, respectively, controlled by I-Mab as described in Appendix 2. 

  
 - 3 - 

	 	1.30	 “I-Mab Parental Antibody Patent Rights” shall
mean any and all Patent Rights Controlled by I-Mab during the Term that claim or cover the composition, use or manufacture of the Parental Antibodies. Such Patent Rights are listed in Appendix 2, as may
be updated from time to time. 

  

	 	1.31	 “Investigation New Drug” or “IND” shall mean a drug that has not been
approved for general use by the U.S. Food and Drug Administration or similar authority in the jurisdiction but is under investigation in clinical trials regarding its safety and effectiveness by clinical investigators and practicing physicians using
patients.  

  

	 	1.32	 “IND Application” shall mean an application for approval of a request for authorization by the
U.S. Food and Drug Administration or similar authority in the jurisdiction to administer an IND to humans. 

  

	 	1.33	 “Joint Committee” or “JC” shall have the meaning ascribed in
Section 6.1. 

  

	 	1.34	 “Know-How” shall mean all biological materials and
other tangible materials, inventions, practices, methods, protocols, formulations, knowledge, information, know-how, trade secrets, processes, assays, skills, experience, techniques and results of
experimentation and testing, which shall include without limitation all biological, chemical, pharmacological, toxicological, clinical, assay, control and manufacturing data, ideas, concepts, drawings, methods of use or application and any other
information, whether patentable or not. 

  

	 	1.35	 “Late Development” shall mean the Research and Development activities after the fulfilment of
Decision Point I prior to the fulfilment of Decision Point II. 

  

	 	1.36	 “Late Development Plan” shall mean, subject to Section 3, a plan for
the Late Development activities to be performed by either Party under this Agreement as attached to this Agreement as Appendix 4 that may be amended from time to time according to Section 6. 

 

	 	1.37	 “Late Development Report” shall mean, subject to Section 3, the
report provided by a Party to the other Party summarizing the Late Development activities it has performed during the past calendar quarter. 

  

	 	1.38	 “Laws” shall mean all laws, statutes, rules, regulations, ordinances and other pronouncements
having the effect of law of any governmental authority, including without limitation patent offices and any other local or national agency, authority court, tribunal, arbitrator, commission, inspectorate, official or other instrumentality of a
government with application within a country. 

  

	 	1.39	 “Net Receipts” shall mean (a) all payments the Parties received from their respective
Out-Licensee under the Out-License Agreement, which shall include but not be limited to upfront payments, technology access fees, milestone payments, financial development funding, commissions, royalties,
success payments as well as acquisition prices allocated to the Products, less (b) any portion of such amounts paid or payable by the Parties to their respective Out-Licensee under the Out-License Agreement that are reasonably allocable to the development, commercialization or manufacture of the Products in or for such portion of licensed territory thereunder and (c) taxes and other
governmental charges occurred in connection with the Out-License Agreement. 

  
 - 4 - 

	 	1.40	 “Net Sales” shall mean the aggregated gross amounts invoiced by the Parties or their
respective Affiliates in respect of the gross sales of all Products under this Agreement by the Parties or their respective Affiliates to Third Parties at an arm’s length open market price less deductions actually allowed in relation to or
specifically allocated to the Products using generally accepted accounting standards for: 

  

	 	1.40.1	 Ordinary and customary quantity, trade and/or cash discounts actually granted and logistics service provider
fees paid and payable; 

  

	 	1.40.2	 Amounts repaid or credited and allowances including cash or credit, given by reason of retroactive price
reductions, or billing errors or rebates actually allowed or paid; 

  

	 	1.40.3	 Amounts refunded or credited for the Products which were rejected, spoiled, damaged, outdated or returned;

  

	 	1.40.4	 Distribution, packing, handling, freight, shipment and insurance costs in transporting the Products to
customers; and 

  

	 	1.40.5	 Taxes and other governmental charges occurred in connection with the sale of Products. 

 

	 	1.41	 “Non-Royalty Income” shall mean the portion of Net
Receipts that is not Royalty Income. 

  

	 	1.42	 “Oa” shall mean the percentage value of royalty and
non-royalty sharing ascribed to ABL Bio in Appendix 5. 

  

	 	1.43	 “Oi” shall mean the percentage value of royalty and
non-royalty sharing ascribed to I-Mab in Appendix 5. 

  

	 	1.44	 “Opt-In Notice” shall have the meaning ascribed in
Section 3.2. 

  

	 	1.45	 “Opt-In Party” shall have the meaning ascribed in
Section 4.3.2. 

  

	 	1.46	 “Opt-Out Party” shall have the meaning ascribed in
Section 4.3.2. 

  

	 	1.47	 “Out-Licensor”, “Out-License” “Out-Licensee”,
“Out-License Agreement” and “Out-License Notice” shall have the meanings ascribed in Section 3.3 and Section 4.

  

	 	1.48	 “Parental Antibody” shall mean each of ABL Bio Parental Antibody and I-Mab Parental Antibody. 

  

	 	1.49	 “Parental Antibody Improvements” shall mean any and all data, results and other Know-How, inventions and developments that constitute improvements to I-Mab Parental Antibody Technology or ABL Bio Parental Antibody Technology, whether patentable or not,
that have been identified, discovered or made by or on behalf of either Party or its Affiliates during the Term and are not specifically designed for BsAb (“I-Mab Parental Antibody
Improvements” and “ABL Bio Parental Antibody Improvements”, respectively). For the avoidance of doubt, Know-How and Patent Rights pertaining solely to the Parental Antibody itself
(but not BsAb Technology) shall be deemed a Parental Antibody Improvement, and any and all improvements to Parental Antibody Technology that are specifically designed for BsAb should be deemed BsAb. 

 

	 	1.50	 “Parental Antibody Know-How” shall mean the Know-How Controlled by I-Mab or ABL Bio during the Term that is reasonably necessary or useful for the practice of the inventions claimed by
I-Mab or ABL Bio under its Parental Antibody Patent Rights (“I-Mab Parental Antibody Know-How” and “ABL
Bio Parental Antibody Know-How”, respectively). 

  
 - 5 - 

	 	1.51	 “Parental Antibody Technology” shall mean the Parental Antibody Patent Rights and the Parental
Antibody Know-How (“I-Mab Parental Antibody Technology” and “ABL Bio Parental Antibody Technology”, respectively).

  

	 	1.52	 “Patent Rights” shall mean all patents and patent applications including without limitation
continuations, continuations-in-part, divisions, patents of addition, utility patents, reissues, renewals, re-examinations,
requests for continued examination, registrations, patents of importation or patent term extensions thereof including Supplemental Protection Certificates (“SPCs”). 

 

	 	1.53	 “PD-L1/4-1BB
BsAb” shall mean the PD-L1 and 4-1BB bi-specific antibody that uses the PD-L1
sequence of I-Mab, and the 4-1BB sequence of ABL Bio. 

  

	 	1.54	 “PD-L1/B7H3 BsAb” shall mean the PD-L1 and B7H3 bi-specific antibody that uses the PD-L1 sequence of I-Mab, and the B7H3
sequence of ABL Bio. 

  

	 	1.55	 “PD-L1/TIGIT BsAb” shall mean the PD-L1 and TIGIT bi-specific antibody that uses the PD-L1 and TIGIT sequence of I-Mab.

  

	 	1.56	 “Product” shall mean a finished pharmaceutical formulation packaged and ready for sale
containing the BsAb. 

  

	 	1.57	 “Product Family” shall mean all Products containing the BsAb. 

 

	 	1.58	 “Project Lead” or “PL” shall have the meaning ascribed in
Section 2.3. 

  

	 	1.59	 “Receiving Party” shall have the meaning ascribed in Section 1.15.

  

	 	1.60	 “Research and Development” shall mean any research and development performed by I-Mab or ABL Bio pursuant to the Research and Development Plan. 

  

	 	1.61	 “Research and Development Plan” shall mean the Early Development Plan, the Late Development
Plan, and Clinical Development Plan. 

  

	 	1.62	 “Royalty Income” shall mean royalty payments, received by either Party or its Affiliates from
a Third Party under the terms and conditions of an Out-License Agreement, which, for the purpose of clarification, shall include payments calculated on the basis of Net Sales generated in connection with such Out-License Agreement. 

  

	 	1.63	 “Term” shall mean the period commencing on the Effective Date ending upon fulfilment of the
last payment obligation of either Party to the other Party hereunder. 

  

	 	1.64	 “Territory” shall mean the following: (1) “ABL Bio’s Territory for PD-L1/TIGIT BsAb” or “ABL Bio’s Territory for PD-L1/B7H3 BsAb” is the Republic of Korea, (2) “ABL Bio’s Territory for PD-L1/4-1BB BsAb” is the Republic of Korea and Greater China (i.e., the People’s Republic of China, Hong Kong, Macao and Taiwan), (3) “I-Mab’s Territory for PD-L1/TIGIT BsAb” or “I-Mab’s Territory for
PD-L1/B7H3 BsAb” is Greater China (i.e., the People’s Republic of China, Hong Kong, Macao and Taiwan) and (4) the “Rest of the World” is all other territories other
than the Republic of Korea and Greater China. The Parties are entitled to the exclusive rights to the development and commercialization of the Product and the Product Family in their respective Territory as specifically defined in this Agreement.

  
 - 6 - 

	 	1.65	 “Third Party” shall mean any other entity than a Party and its Affiliates.

  

	 	1.66	 In this Agreement unless it is inconsistent with the context, a reference to a statutory provision includes a
reference to: (i) a statutory amendment, modification, substitution, consolidation or re-enactment (whether before or after Effective Date); (ii) statutory instruments or subordinate legislation or orders
made under the statutory provision; and (iii) statutory provisions of which the statutory provision is an amendment, modification, substitution, consolidation or re-enactment. Unless the context of this
Agreement otherwise requires, (i) words of one gender includes the other gender; (ii) words using the singular or plural number also include the plural or singular number respectively; (iii) the terms “hereof”,
“herein”, “hereby” and derivative or similar words refer to this entire Agreement; and (iv) the terms “Article”, “Section” and “Appendix” refer to the specified Article, Section and Appendix of
this Agreement. When this Agreement refers to a number of days, unless otherwise specified (e.g. Business Days), such number shall refer to calendar days. When this Agreement refers to a number of years and/or months, unless otherwise specified,
such number shall refer to calendar years and/or months. 

  

	2.	 Early Development 

 

	 	2.1	 The Parties have agreed to share activities according to the Early Development Plan attached hereto as
Appendix 3 up to Decision Point I. Such Early Development Plan provides the planned activities of each Party and shall be updated, if required, by mutual agreement between the Parties. 

 

	 	2.2	 All Early Development shall be performed according to the Early Development Plan by each Party (and/or its
Affiliate or permitted CRO) as assigned to it therein. In principle, the Parties agreed to share the cost and responsibility for Early Development in the Rest of the World equally with Commercially Reasonable Efforts. However, for the purpose of
administrative convenience, the Parties agree to share the costs for Early Development as follows: 

  

	 	2.2.1	 Each Party is responsible to bear their respective costs for any and all
in-house work to be performed by each Party until the production of selected candidates prior to in vivo proof of concept experiments in accordance with the roles assigned to the Party as outlined in
the Early Development Plan and Exhibit A of the Materials Transfer Agreement. 

  

	 	2.2.2	 Any and all the costs associated with the subsequent in vivo experiments, including without limitation
in vivo experiments performed by I-Mab and the permitted CRO, will be split 50%:50% between the Parties 

  

	 	(a)	 Within thirty (30) days after the end of each calendar quarter, all parties (excluding I-Mab but including all permitted CROs) shall submit to ABL Bio a reasonably detailed report setting forth the cost and expense (including both in house and external costs and expenses) incurred by such party to
perform the in vivo experiments activities. 

  

	 	(b)	 ABL Bio shall, within thirty (30) days after the receipt of such reports, prepare a consolidated report,
subject to approval by the other Party; 

  
 - 7 - 

	 	(c)	 A Party which has borne and expended more than its share of the in vivo experiments costs shall submit
to the other Party an invoice for such exceeded amount so that the total cost can be borne by the Parties (50%:50%). The other Party shall pay such invoice within sixty (60) days after receipt. Each Party shall keep detailed books and records
of the development cost incurred by such Party to in vivo experiments activities and shall make such books and records available to the other Party for inspection and audit upon reasonable advance notice. 

 

	 	2.3	 Project Lead. Promptly after the Effective Date, the Parties will appoint a Project Lead (the
“PL”) for each project to facilitate the communication of the Early Development activities. Each Party shall appoint its respective PL within thirty (30) days after the Effective Date, and may substitute its PL, in its sole
discretion, effective upon written notice to the other Party of such change. Each Party’s PL shall be a project manager and will have appropriate expertise and ongoing familiarity with the Research and Development Plans. The PLs shall keep each
other informed of all details of the activities under the Early Development Plan and the Late Development Plan, subject to Section 3. The PL responsibilities shall include (i) scheduling meetings, including the JC;
(ii) setting the agenda for such meetings with solicited input from other members, including the JC. 

  

	 	2.4	 Each Party shall provide the other Party with disclosure of any invention made by that Party during the
Research and Development comprising BsAb Technology Improvements, BsAb Improvements, and Parental Antibody Improvements. 

  

	3.	 Late Development, Clinical Development and Options 

 

	 	3.1	 At Decision Point I and, in the event the JC decides to develop and commercialize any Product in the Rest of
the World, at each Decision Point after Decision Point I, if one Party owns more than 50% of the intellectual property rights for a particular project as determined in accordance with Appendix 5, such Party shall be the Lead Party; if neither
party owns more than 50% of the intellectual property rights for the project, the JC shall select a Party as the Lead Party within seven (7) Business Days after the completion of Decision Point I. For the avoidance of doubt, in the case
of PD-L1/TIGIT, I-Mab shall be the Lead Party, and in the case of PD-L1/4-1BB and PD-L1/B7H3, ABL Bio and I-Mab own 50% respectively and the Lead Party shall be determined by the JC within seven (7) Business Days after Decision Point I. Decisions
regarding Late Development, Clinical Development and entering into Out-License Agreement will be made in the following manner: in ABL Bio’s Territory by ABL Bio, in
I-Mab’s Territory by I-Mab, and in the Rest of the World, by the Lead Party. 

 

	 	3.2	 The Parties agree to co-develop each of the Products containing PD-L1/TIGIT, PD-L1/4-1BB and PD-L1/B7H3 up to Decision Point II and share the cost and
responsibilities equally with Commercially Reasonable Efforts in accordance with the Late Development Plan attached hereto as Appendix 4. No later than seven (7) Business Days following each Decision Point II, III or IV, either Party can
notify the other Party that it intends to share the costs of the next development work with the other Party in the Rest of the World (“Opt-In Notice”). After an Opt-In Notice from a Party, such Party shall automatically become the Lead Party if the other Party has not given a similar notice. For the avoidance of doubt, if one Party stops development work or sharing the
costs of development work, the other Party who continues development work or bears the cost of such development work shall automatically become the Lead Party. 

 

	 	3.3	 ABL Bio in ABL Bio’s Territory, and I-Mab in I-Mab’s Territory, has the right to pursue indirect development and commercialization of the Products via an Out-License Agreement (“Out-License Agreement”) with any Third Party (“Out-Licensee”). The Party who enters into an Out-License
Agreement in its Territory shall make a commercially reasonable effort to obtain the consent of such Out-Licensee to disclose relevant information (excluding financial terms) regarding such Out-License
Agreement with the other Party after the execution. In the Rest of the World, either Party may pursue out-license opportunities, but the final decision to enter into an Out-License Agreement with any Out-Licensee to indirectly develop and commercialize the Product (“Out-License”) in any country in the Rest of the World should be made by the Lead Party (a
Party entering into an Out-License Agreement hereinafter referred to as “Out-Licensor”). Out-Licensor shall
notify the other Party of the decision (“Out-License Notice”) and, subject to consent of the Out-Licensee, provide the other Party with a complete copy
of each Out-License Agreement within thirty (30) days of the execution of such agreement, which shall not be unreasonably withheld or delayed. 

  
 - 8 - 

	 	3.4	 At Decision Point I and, if both Parties decide to co-develop the
Products in the Rest of the World, at each Decision Point after Decision Point I, according to Section 3.1, the Lead Party shall, within ninety (90) days of such decision, convene a JC meeting for and agree to an
amended Late Development Plan, the Clinical Development Plan, and the budget. 

  

	 	3.4.1	 The PLs shall continue their responsibilities according to Sections 6.4 and 2.3 during the Late
Development and the Clinical Development; 

  

	 	3.4.2	 The JC shall discuss and approve any further changes to the Late Development Plan and the Clinical Development
Plan in case of co-development and the budget proposed by the Parties; 

  

	 	3.4.3	 All Late Development and Clinical Development shall be performed according to the Late Development Plan and
Clinical Development Plan by each Party (and/or its Affiliate or permitted CMO/CRO) as assigned to it therein. Each Party shall use Commercially Reasonable Efforts to perform the Late Development and Clinical Development activities assigned to it
and shall provide Late Development Report and Clinical Development Report to the other Party. Subject to the terms of this Agreement, the Lead Party may enter into a service agreement or collaboration agreement, without the other Party’s prior
written consent, with (i) its Affiliate and (ii) any Third Party acting solely as contract manufacturer, contract research organization, distributor or wholesaler of the Party or its Affiliates. A Party who enters into a service agreement
or a collaboration agreement with its Affiliate or a Third Party shall, subject to consent of such Affiliate or Third Party, provide the other Party with a complete copy of such an Agreement within thirty (30) days of the execution of such
agreement, which shall not be unreasonably withheld or delayed. 

  

	 	3.4.4	 the Parties shall share the Late Development and Clinical Development cost as follows. 

 

	 	(a)	 Within fifteen (15) Business Days after the end of each calendar quarter, the other Party (i.e.,
the party that is not the Lead Party) shall submit to the Lead Party a reasonably detailed report, together with evidence, setting forth the cost and expense (including both in house cost and expense at an FTE rate of USD 200,000 per year and
external cost and expense) in such calendar quarter incurred by such Party to perform the Late Development or Clinical Development activities assigned to it under the Late Development Plan or Clinical Development Plan. 

  
 - 9 - 

	 	(b)	 If there is any question in the report prepared by the other Party, the Lead Party may request the other Party
to supplement within fifteen (15) Business Days after receiving the detailed report from the other Party. Otherwise, the Lead Party shall prepare a consolidated report (summary of the cost and expense incurred by both the Lead Party and the
other Party) within fifteen (15) Business Days after receiving the detailed report from the other Party, subject to approval by the other Party. The other Party should give the Lead Party a written notice within fifteen (15) Business Days
if there is any question in such consolidated report. 

  

	 	(c)	 Upon receipt of such written notice within the required time, the Lead Party may provide a revised consolidated
report to the other Party. If the Lead Party does not receive such a written notice within the required time, the Lead Party shall invoice the other Party according to the Development Costs Sharing (Ca: Ci) as specified in Appendix 5. The
other Party shall pay such invoice within sixty (60) days after the invoice date. 

  

	 	(d)	 The total cost and expense, unless specifically approved by the JC, shall not exceed one hundred and ten
percent (110%) of the amount set forth in the budget for such Late Development activities in the Late Development Plan or Clinical Development activities in the Clinical Development Plan. 

 

	 	(e)	 Each Party shall keep detailed books and records of the development cost incurred by such Party to perform Late
Development or Clinical Development activities and shall make such books and records available to the other Party for inspection and audit upon reasonable advance notice. 

 

	 	3.5	 Immediately after the execution of this Agreement, neither Party shall develop independently from the other
Party or with any Third Party a bispecific antibody that uses the same pair of antibodies as the BsAb under this Agreement for bispecific antibody development, even if the latter bispecific antibody contains a different sequence than what was
contained in the particular BsAb. In the event that both Parties agree, by signing an amendment at any time, that such a bispecific antibody that uses such pair of antibodies under this Agreement has no drug developability, such bispecific antibody
that uses such pair of antibodies should not be limited by this Section 3.5. 

  

	 	3.6	 Each Party should share the clinical data generated during its development work with the other Party without
additional charge. Each Party should provide reasonable technical assistance regarding relevant documents, material, and technical transfer as reasonably requested by the other Party in accordance with, and at the FTE rate set forth in
Section 3.4.4. 

  

	4.	 Out-License Income Sharing and Royalty Incoming
Sharing 

  

	 	4.1	 Out-License Right. The final decision to enter an Out-License Agreement with a Third Party in the Rest of the World should be made by the Lead Party. All other Out-License Agreements shall require the prior written consent of
the other Party, which shall not be unreasonably withheld, delayed or conditioned. A Party who enters an Out-License Agreement or Sublicense Agreement with a Third Party shall provide the other Party with a
complete copy of each Out-License Agreement within thirty (30) days of the execution of such agreement. 

  
 - 10 - 

	 	4.2	 Party’s Territory. 

 

	 	4.2.1	 When either Party or its Affiliate Out-Licenses the Products in the Party’s Territory, such Party shall
not pay the other Party royalties or out-licensing incoming sharing on Net Sales of all Products in the Party’s Territory. 

 

	 	4.3	 Rest of the World. 

In the event the JC decides to develop and commercialize the Products at any Decision Point in the Rest of the World, income sharing shall be
done in the following manner. 
  

	 	4.3.1	 Non-Royalty Income Sharing. After any Decision Point if both
Parties decide to participate in the development of a Product in any country in the Rest of the World and execute an Out-License Agreement for the country, ABL Bio shall be entitled to a share (Oa) of the Non-Royalty Income, and I-Mab shall be entitled to a share of (Oi) of the Non-Royalty Income as specified in Appendix 5;

  

	 	4.3.2	 Non-Royalty Income Sharing Adjustment in case of Opt-Out. After any Decision Point except Decision Point I, if a Party (“Opt-Out Party”) decides not to participate in the development of the Product(s) in the Rest of the World and the
other Party (“Opt-In Party”) executes an Out-License Agreement in the Rest of the World, the Opt-In Party shall pay to the Opt-Out Party a percentage of the Out-License income, which percentage shall equal to [X/(X+Y*1.5)] where, 

 

	 	(a)	 X is the total amount actually incurred (either paid or shared) by the
Opt-Out Party to develop the Product under this Agreement before discontinuing the participation; and 

  

	 	(b)	 Y is the total amount actually incurred (either paid or shared) by the
Opt-In Party to develop the Product under this Agreement before the execution of such Out-License Agreement; 

 

	 	4.3.3	 Royalty Income Sharing. After any Decision Point if both Parties decide to participate in the
development of a Product in any country in the Rest of the World and execute an Out-License Agreement for the country, ABL Bio shall be entitled to a share (Oa) of the Royalty Income, and I-Mab shall be entitled to a share of (Oi) of the Royalty Income as specified in Appendix 5. 

  

	 	4.3.4	 Royalty Income Sharing Adjustment in case of Opt-Out. After any
Decision Point except Decision Point I, if a Party decides not to participate in the development of the Product(s) in the Rest of the World and the other Party executes an Out-License Agreement in the Rest of
the World, the Opt-In Party shall pay to the Opt-Out Party a minimal percentage of the Royalty Income as follows: when I-Mab or
its Affiliate out-licenses the Products in the Rest of the World, I-Mab shall pay ABL Bio a percentage of the royalties, which percentage shall be no less than 5%*Oa;
when ABL Bio or its Affiliate Out-Licenses the Products in the Rest of the World, ABL Bio shall pay I-Mab a percentage of the royalties, which percentage shall be no less than 5%*Oi as specified in Appendix
5. 

 Example: If ABL Bio decides not to participate in the development of the Product(s) for PD-L1/TIGIT BsAb after any Decision Point except Decision Point I, and I-Mab Out-Licenses the Product(s) to a Third Party with 10% royalty in any country in the Rest of World,
then I-Mab shall pay ABL Bio 1.5% (= 5%*Oa) of the Royalty Income. 

  
 - 11 - 

	5.	 Payments 

 

	 	5.1	 The payments under Section 4 above are expressly stated as exclusive of Value Added
Tax or equivalent sales tax applicable (“VAT”). If VAT is or may become lawfully payable or chargeable in respect of a payment, then the Party receiving such Payment will promptly provide a valid VAT invoice to the Party making such
Payment. If the VAT charged to and paid by the Party making such Payment is subsequently refunded by any relevant fiscal authority having oversight of either Party, then such refund shall be promptly forwarded to the Party who paid for the VAT with
a valid VAT credit note. At the request of the other Party, either Party shall give the other Party the assistance as may be required by the relevant tax authority, to claim exemption from or reduction of the VAT. 

 

	 	5.2	 If any withholding tax applies to any amount due to either Party under this Agreement, such amount of
withholding tax due will be deducted from the amount to be paid to either Party and paid to the appropriate tax authorities in a timely manner. At the request of the other Party, either Party shall give the other Party the assistance as may be
required by the relevant tax authority, to claim exemption from or reduction of such withholding tax imposed on the amount. The other Party will provide either Party written evidence of its payment of any such withholding tax. 

 

	 	5.3	 Parties and their respective Affiliates shall keep complete and accurate books and records used in the
determination of all Net Sales, payments and deliveries of the Products to Third Parties for a period of ten (10) years. Either Party shall, not more than once a calendar year, have the right to appoint an independent certified public
accountant or like person (the “Auditor”) reasonably acceptable to the other Party, to perform an audit at the other Party’s site upon at least ten (10) Business Days’ prior written notice and within normal business
hours. The other Party shall provide all books and records necessary for the Auditor to determine Net Sales, payments and deliveries under this Agreement. The cost of such audit shall not be borne by the other Party, except for the event that the
audit results determine a shortfall of reported Net Sales greater than two percent (2%). 

  

	 	5.4	 The other Party shall adhere to the payment terms described in Section 4. An interest
of 0.1% per day shall accrue on the total amount of late payment from the day when the corresponding payment becomes due and payable. 

  

	 	5.5	 The Party shall make all the payments to the other party under this Agreement in US Dollar (USD),
including, but not limited to, Net Sales and Net Receipts in currencies other than USD shall be converted into USD using the average of the respective exchange rate as published by Bloomberg for the respective quarter. All the payments will be made
without deduction of exchange, collection or other charges. 

  

	6.	 Contract Governance 

 

	 	6.1	 Joint Committee. Promptly after the Effective Date the Parties will establish a joint committee to
facilitate the performance and oversight of the Research and Development Plan (the “JC”). The JC will be comprised of an equal number of representatives from either Party, at least two (2) named representatives of I-Mab and at least two (2) named representatives of ABL Bio. Each Party shall appoint its respective representatives to the JC within thirty (30) days after the Effective Date, and may substitute one or
more of its representatives, in its sole discretion, effective upon notice to the other Party of such change. Each Party shall have a JC representative who is a senior employee (Vice President level or above), and each JC representative will have
appropriate expertise and ongoing familiarity with the Research and Development Plans. Additional representatives may from time to time, by mutual consent of the Parties, be invited to attend JC meetings, subject to such representatives’
written agreement to comply with the requirements of Section 8. All proceedings for the JC shall take place in English. Each Party shall bear its own expenses relating to attendance at such meetings by its representatives.

  
 - 12 - 

	 	6.2	 Meetings. The JC shall meet in accordance with a schedule established by agreement of the Parties, but
no less frequently than once per calendar quarter, with the location for such meetings alternating between I-Mab and ABL Bio facilities (or such other locations as are determined by the JC). Alternatively, the
JC may meet by means of teleconference, videoconference or other similar communications equipment, but at least one meeting per year shall be conducted in person. Each Party shall nominate a chairperson (each, a “JC Chairperson”)
with equal voting rights on each decision. 

  

	 	6.3	 JC Responsibilities. The JC shall (i) monitor progress under the Research and Development Plans,
review relevant data and share information on progress of the Research and Development with the Parties, (ii) review and approve any proposed updates to the Early Development Plan and, subject to Section 3, the Late
Development Plan and Clinical Development Plan, (iii) discuss and consult regarding any technical or scientific difficulties encountered under a Research and Development Plan, (iv) perform such other activities as the Parties agree in
writing shall be the responsibility of the JC, (v) decide which Product to develop and commercialize, (vi) review and approve amended Research and Development Plan and the budget, and (vii) select a Party as the Lead Party of each
project in the Rest of the World within seven (7) Business Days after the completion of Decision Point I. For avoid of the doubt, the Lead Party may be changed at any Decision Point by vote in JC or the consent of the Parties.

  

	 	6.4	 The PL shall be responsible for (i) scheduling meetings at least once per calendar quarter, but more
frequently as the JC determines it necessary; (ii) setting agenda for meetings with solicited input from other members; (iii) confirming and delivering minutes to the JC for review and final approval; and (iv) conducting effective
meetings, including ensuring that objectives for each meeting are set and achieved. Each Party will provide the members of the JC with written copies of all materials they intend to present at a JC meeting. In the absence of a PL, the tasks assigned
to the PL in this Section 6.4 shall be assigned to the JC Chairperson. 

  

	 	6.5	 All decisions of the JC shall be made by consensus, with each Party having collectively one (1) vote in
all decisions. If after reasonable discussion and good faith consideration of both Party’s views on a particular matter before the JC, the JC is still unable after a period of ten (10) days to reach a unanimous decision on such matter,
then either Party may, by written notice to the other, have such matter referred to the CEOs of the Parties for resolution. If the CEOs are able to resolve such matter within the thirty (30) day period, then: (a) with respect to the Early
Development Plan, the status quo (including the existing budget) shall persist until the Parties reach agreement with respect to any amendment thereto; and (b) I-Mab in
I-Mab’s Territory, ABL Bio in ABL Bio’s Territory, and the developing Party(ies) in the Rest of the World shall have the right to approve amendments to the Late Development Plan and Clinical
Development Plan. 

  

	7.	 Diligence and Reports 

 

	 	7.1	 Each Party agrees to maintain proper records (the “Records”) in respect of its performance of
the Research and Development, including the procedures, techniques and methodologies used, the progress made, and any inventions conceived and/or reduced to practice or otherwise made as part of the Research and Development. In order to file,
prosecute and defend and Patent Rights claiming any BsAb Improvement, BsAb Technology Improvement, or Parental Antibody Improvement, each Party shall upon request of the other Party, which shall not be unreasonably made, (a) make the Records
available to the other Party or its designee for inspection; and (b) provide copies of the Records or any part(s) thereof to the other Party or its designee. As part of keeping the Records, each Party shall ensure that all of its personnel and
all of its agents that are involved in the Research and Development will keep accurate laboratory notebooks, that: (i) shall be duly signed, dated and witnessed; and (ii) shall be created and maintained in accordance with its standard
operating procedures that would be sufficient to allow for said laboratory notebooks to be used in any proceedings before the relevant governmental authorities in the relevant Territory, in order to establish the date of invention for any inventions
in according with the patent Laws applicable in the relevant Territory. 

  
 - 13 - 

	 	7.2	 Each calendar quarter until expiration of the royalty payment or income sharing obligation under
Section 4, each Party shall provide to the other Party reports as follows: 

  

	 	7.2.1	 Each Party shall provide to the other Party an Early Development Report within thirty (30) days after the
end of each calendar quarter during Early Development including all the results obtained in the past calendar quarter (including without limitation all raw data). 

 

	 	7.2.2	 Regardless of whether a Party participates in Late Development or Clinical Development, each Party shall
provide to the other Party a Late Development Report or Clinical Development Report within thirty (30) days after the end of each calendar quarter during Late Development or Clinical Development including all the results obtained in the past
calendar quarter (including without limitation all raw data). 

  

	 	7.2.3	 Upon and after the launching of the Product or Product Family, I-Mab
and ABL Bio shall provide a biannual report to each other providing a high-level overview of all material commercial activities in the respective territories for the Product within thirty (30) days after the end of each six-month period. 

  

	8.	 Confidentiality Obligations 

 

	 	8.1	 In consideration of disclosure of Confidential Information by the Disclosing Party, the Receiving Party
undertakes: 

  

	 	8.1.1	 to keep the Confidential Information secret and confidential at all times; 

 

	 	8.1.2	 not to disclose or permit the disclosure of any Confidential Information of the Disclosing Party, in whole, in
part, or in summary, to any person, except as expressly permitted by this Agreement; 

  

	 	8.1.3	 not to use the Confidential Information of the Disclosing Party or permit it to be used, in whole or in part,
for any purpose other than the performance of its obligations or exercise of its rights under this Agreement; 

  

	 	8.1.4	 to take all proper and reasonable measures to ensure the confidentiality of the Confidential Information of the
Disclosing Party, including but not limited to applying the same security measures and degree of care to such Confidential Information as the Receiving Party applies to its own confidential information; and 

  
 - 14 - 

	 	8.1.5	 to inform the Disclosing Party immediately if it becomes aware of the possession, use or knowledge of any of
the Confidential Information of the Disclosing Party by an unauthorised person, and to provide any assistance in relation to such unauthorised possession, use or knowledge that the Disclosing Party may reasonably require. 

 

	 	8.2	 Exceptions to Confidentiality Obligations 

 

	 	8.2.1	 The Receiving Party’s obligations of confidentiality and non-use
under this Agreement shall not apply to any Confidential Information of the Disclosing Party that the Receiving Party can prove by means of reasonable written evidence: 

 

	 	(a)	 was known to the Receiving Party on a non-confidential basis prior to
disclosure by the Disclosing Party; or 

  

	 	(b)	 is or becomes publicly known other than as a result of breach of this Agreement by the Receiving Party or by
anyone to whom the Receiving Party disclosed the Confidential Information of the Disclosing Party; or 

  

	 	(c)	 is received by the Receiving Party without restriction on disclosure or use from a Third Party lawfully
entitled to make the disclosure without such restrictions; or 

  

	 	(d)	 is developed by any of the Receiving Party’s or its Affiliate’s directors, employees, consultants,
advisors or agents (collectively, “Representatives”) who have not had any direct or indirect access to, or use or knowledge of, the Confidential Information of the Disclosing Party; 

except that the above exceptions do not extend to circumstances where the Confidential Information is (i) specific, does not fall within
the above exceptions, and is embraced by more general information which does fall within the above exceptions or (ii) a combination of information in the public domain separated across multiple sources. 

 

	 	8.2.2	 The Receiving Party will not be in breach of its obligations under this Agreement to the extent that it is
required to disclose Confidential Information of the Disclosing Party by law (provided, in the case of a disclosure under any freedom of information legislation, that the exemptions under that legislation do not apply) or order of a court or other
public body that has jurisdiction over it, provided that, before making such a disclosure, the Receiving Party shall, to the extent it is legally permitted to do so: 

 

	 	(a)	 inform the Disclosing Party of the proposed disclosure as soon as possible, and if possible before the court or
other public body orders the disclosure; 

  

	 	(b)	 take into account reasonable requests of the Disclosing Party in relation to such disclosure;

  
 - 15 - 

	 	(c)	 ask the court or other public body to treat such Confidential Information as confidential; and

  

	 	(d)	 permit the Disclosing Party to make representations to the court or other public body in respect of the
disclosure and/or confidential treatment of such Confidential Information. 

  

	 	8.3	 Disclosure to Representatives 

 

	 	8.3.1	 The Receiving Party shall permit access to the Confidential Information of the Disclosing Party only to those
of its representatives who: 

  

	 	(a)	 reasonably require such access for performing its obligations or exercising its rights under this Agreement;

  

	 	(b)	 have been informed of the confidential nature of such Confidential Information, the Disclosing Party’s
interest in such Confidential Information, and the provisions of this Agreement, and have been instructed to comply with this Agreement; and 

  

	 	(c)	 have entered into legally binding confidentiality obligations to the Receiving Party on terms that are no less
onerous than those set out in this Agreement, and which extend to such Confidential Information. 

  

	 	8.3.2	 The Receiving Party shall ensure that all those representatives who have access to the Confidential Information
of the Disclosing Party comply with the provisions of this Agreement, and the Receiving Party shall be liable to the Disclosing Party for any breach of this Agreement by the Receiving Party’s Representatives. 

 

	 	8.4	 Upon expiration or termination of this Agreement, 

 

	 	8.4.1	 At the Disclosing Party’s written request, the Receiving Party shall; 

 

	 	(a)	 immediately return to the Disclosing Party (or, if the Disclosing Party so requests, destroy or erase) all
Confidential Information of the Disclosing Party that the Receiving Party has received under this Agreement including any copies made and permanently delete all electronic copies of any such Confidential Information from the Receiving Party’s
computer systems; 

  

	 	(b)	 provide to the Disclosing Party a certificate, signed by an officer of the Receiving Party, confirming that the
obligations in this Section 8.4 have been complied with; and 

  

	 	(c)	 make no further use of any such Confidential Information. 

The Receiving Party may, however, keep one copy of the Confidential Information of the Disclosing Party in its legal advisor’s files
solely for the purpose of enabling it to comply with the provisions of this Agreement. 

  
 - 16 - 

	 	8.5	 As between the parties, except as otherwise expressly set forth in this Agreement: 

 

	 	8.5.1	 the Confidential Information of the Disclosing Party is proprietary to the Disclosing Party and the Disclosing
Party reserves all rights in such Confidential Information; 

  

	 	8.5.2	 the Disclosing Party is the sole owner of all property rights in tangible records of the Confidential
Information of the Disclosing Party; and 

  

	 	8.5.3	 the Disclosing Party is and shall remain the sole owner of all intellectual property rights in the Confidential
Information of the Disclosing Party. 

  

	 	8.6	 No rights in respect of the Confidential Information of the Disclosing Party are granted to the Receiving
Party, other than to use it in accordance with the terms of this Agreement, and no obligations are imposed on the Disclosing Party other than those expressly stated in this Agreement. In particular, nothing in this Agreement shall be construed or
implied as obliging the Disclosing Party to disclose any specific type of information under this agreement, whether Confidential Information or not. 

  

	 	8.7	 The Receiving Party agrees that any breach of its obligations of confidentiality and non-use under this Agreement will cause irreparable harm to the Disclosing Party; therefore, the Disclosing Party shall have, in addition to any remedies available at law, the right to obtain equitable relief to
enforce this Agreement. 

  

	 	8.8	 The confidentiality obligations under this Section shall, notwithstanding any termination of discussions
between the Parties, continue in force for a period of seven (7) years after the expiration or termination of this Agreement. Notwithstanding the foregoing, the non-disclosure and non-use obligations imposed by this Agreement with respect to trade secrets included in the Confidential Information of a Party will continue for as long as such Party continues to treat such Confidential
Information as a trade secret. 

  

	 	8.9	 The Parties agree to make a joint press release according to Appendix 6 of this Agreement. Regarding any
other information not expressly contained in such joint press release, except for disclosure required by applicable laws, neither Party shall make, or permit any person to make, any public announcement concerning this Agreement without the prior
written consent of the other Party (such consent not to be unreasonably withheld or delayed). 

  

	9.	 Representation and Warranties 

 

	 	9.1	 Each Party represents and warrants to the other Party that as of the Effective Date: 

 

	 	9.1.1	 Such Party (i) is a company duly organized, validly existing and in good standing under the Laws of the
jurisdiction of its organization; (ii) has the requisite corporate power and authority and the legal right to conduct its business as now conducted and hereafter contemplated to be conducted; and (iii) has or will obtain all necessary
licenses, permits, consents, or approvals from or by, and has made or will make all necessary notices to, all governmental authorities having jurisdiction over such Party, required for the performance of this Agreement. 

 

	 	9.1.2	 The execution, delivery and performance of this Agreement by such Party (i) are within the corporate power
of such Party; (ii) have been duly authorized by all necessary or proper corporate action; (iii) do not conflict with any provision of the organizational documents of such Party; (iv) will not, to the best of such Party’s
knowledge, violate any Laws or any order or decree of any court or governmental authority; and (v) will not violate or conflict with any terms of any indenture, mortgage, deed of trust, lease, agreement or other instrument to which such Party
is a party, or by which such Party is bound; 

  
 - 17 - 

	 	9.1.3	 This Agreement has been duly executed and delivered by such Party and constitutes a legal, valid and binding
obligation of such Party, enforceable against such Party in accordance with its terms, subject to bankruptcy, insolvency, reorganization, arrangement, winding-up, moratorium, and similar laws of general
application affecting the enforcement of creditors’ rights generally, and subject to general equitable principles, including the fact that the availability of equitable remedies, such as injunctive relief or specific performance, is in the
discretion of the court. 

  

	 	9.2	 Each Party represents, warrants and covenants that neither it nor any of its Affiliates has been Debarred or is
subject to Debarment and neither it nor any of its Affiliates will use in any capacity, in connection with the Research and Development, any person or entity who has been Debarred. Each Party agrees to inform the other Party in writing immediately
if it or any person or entity who is performing Research and Development under this Agreement is Debarred, or if any action, suit, claim, investigation or legal or administrative proceeding is pending or, to such Party’s knowledge, is
threatened, relating to the Debarment of such Party or any person or entity used in any capacity by such Party or any of its Affiliates in connection with the Research and Development. 

 

	 	9.3	 ABL Bio represents and warrants to I-Mab that as of the Effective Date,
ABL Bio is the lawful owner of all right, title and interest in and to the BsAb Technology, the ABL Bio Parental Antibody Patent Rights and ABL Bio Parental Antibody Know-How. As of the Effective Date, ABL Bio
has no knowledge of any claim made against it (x) asserting the invalidity, misuse, unregisterability or unenforceability of any of the BsAb Technology and the ABL Bio Parental Antibody Patent Rights or (y) challenging ABL Bio’s
Control of BsAb Technology, ABL Bio Parental Antibody Patent Rights or ABL Bio Parental Antibody Know-How or making any adverse claim of ownership of BsAb Technology, ABL Bio Parental Antibody Patent Rights or
ABL Bio Parental Antibody Know-How. 

  

	 	9.4	 I-Mab represents and warrants to ABL Bio that as of the Effective Date,
I-Mab is the lawful owner of all right, title and interest in and to the I-Mab Parental Antibody Patent Rights and I-Mab Parental
Antibody Know-How. As of the Effective Date, I-Mab has no knowledge of any claim made against it (x) asserting the invalidity, misuse, unregisterability or
unenforceability of any of the I-Mab Parental Antibody Patent Rights or (y) challenging I-Mab’s Control of I-Mab
Parental Antibody Patent Rights or I-Mab Parental Antibody Know-How or making any adverse claim of ownership of the I-Mab
Parental Antibody Patent Rights or I-Mab Parental Antibody Know-How. 

  

	 	9.5	 THE EXPRESS REPRESENTATIONS AND WARRANTIES OF THE PARTIES STATED IN THIS SECTION 9 ARE IN LIEU OF ALL OTHER
REPRESENTATIONS AND WARRANTIES, EXPRESS, IMPLIED, OR STATUTORY, INCLUDING WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT OR
NON-MISAPPROPRIATION OF THIRD PARTY INTELLECTUAL PROPERTY RIGHTS. 

  

	10.	 Indemnification 

 

	 	10.1	 Subject to the other provisions of this Section, ABL Bio shall defend, indemnify and hold harmless I-Mab, its Affiliates, and each of their officers, directors, shareholders, employees, successors and assigns from and against all Third Parties claims, suites, losses, liabilities, damages, costs, fees and expenses
(including reasonable attorney’s fee), to the extent arising out of (i) ABL Bio’s negligence or willful misconduct in performing any of its obligations under this Agreement, or (ii) breach by ABL Bio of any of its
representations, warranties, covenants or agreements under this Agreement, except in each case to the extent such claims arise from a matter for which I-Mab is obligated to indemnify ABL Bio under
Section 10.2. 

  
 - 18 - 

	 	10.2	 Subject to the other provisions of this Section, I-Mab shall defend,
indemnify and hold harmless ABL Bio, its Affiliates, and each of their officers, directors, shareholders, employees, successors and assigns from and against all Third Parties claims, suites, losses, liabilities, damages, costs, fees and expenses
(including reasonable attorney’s fee), to the extent arising out of (i) I-Mab’s negligence or willful misconduct in performing any of its obligations under this Agreement, or (ii) breach by
I-Mab of any of its representations, warranties, covenants or agreements under this Agreement, except in each case to the extent such claims arise from a matter for which ABL Bio is obligated to indemnify I-Mab under Section 10.1. 

  

	 	10.3	 Each Party (“Indemnified Party”) will promptly notify the other Party (“Indemnifying
Party”) in writing if it becomes aware of a claim (actual or potential) by any Third Party or any proceeding (including any investigation by a governmental authority) (“Third Party Claim”) for which indemnification may be
sought and will give such related information as the Indemnifying Party shall reasonably request. 

  

	 	10.4	 To be eligible to be indemnified hereunder, the Indemnified Party will provide the Indemnifying Party with
prompt notice of the claim giving rise to the indemnification obligation pursuant to this Section 10.4 and the exclusive ability to defend (with the reasonable cooperation of the Indemnified Party) or settle any such claim;
provided, however, that the Indemnifying Party will not enter into any settlement for damages other than monetary damages without the Indemnified Party’s written consent, such consent not to be unreasonably withheld. The
Indemnified Party has the right to participate, at its own expense and with counsel of its choice, in the defense of any claim or suit that has been assumed by the Indemnifying Party. If the Parties cannot agree as to the application of Sections
10.1 and 10.2 to any particular Third Party Claim, the Parties may conduct separate defenses of such Third Party Claim. Each Party reserves the right to claim indemnity from the other in accordance with Sections 10.1 and
10.2 above upon resolution of the underlying claim, notwithstanding the provisions of this Section 10.4 requiring the Indemnified Party to tender to the Indemnifying Party the exclusive ability to defend such claim
or suit. 

  

	 	10.5	 NEITHER PARTY WILL BE LIABLE UNDER ANY LEGAL THEORY (WHETHER TORT, CONTRACT OR OTHERWISE) FOR SPECIAL,
INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES ARISING OUT OF OR RELATED TO THIS AGREEMENT OR THE EXERCISE OF ITS RIGHTS HEREUNDER, INCLUDING LOST PROFITS ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF SUCH
DAMAGES, EXCEPT AS A RESULT OF A MATERIAL BREACH OF THE CONFIDENTIALITY AND NON-USE OBLIGATIONS IN SECTION 8. NOTHING IN THIS SECTION 10.5 IS INTENDED TO LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR
OBLIGATIONS OF EITHER PARTY. 

  

	11.	 Intellectual Property Rights, BsAb Technology and BsAb Improvements, Parental Antibody Technology and
Parental Antibody Improvements. 

  

	 	11.1	 Each Party shall have and retain sole and exclusive title to their respective intellectual property rights. For
avoidance of doubt, as between the Parties, ABL Bio shall own and retain all rights to the BsAb Technology (including BsAb Technology Improvements) and ABL Bio Parental Antibody Technology (including ABL Bio Parental Antibody Improvements), and I-Mab shall retain all rights to I-Mab Parental Antibody Technology (including I-Mab Parental Antibody Improvements). ABL Bio grants I-Mab right to exploit (including right to grant sub-license for the purpose of Out-License) the intellectual property rights in the
BsAb Technology (including BsAb Technology Improvements) and ABL Bio Parental Antibody Technology (including ABL Bio Parental Antibody Improvements) within the scope of this Agreement, and I-Mab grants ABL Bio
right to exploit (including right to grant sub-license for the purpose of Out-License) the intellectual property rights in I-Mab
Parental Antibody Technology (including I-Mab Parental Antibody Improvements) within the scope of this Agreement. 

  
 - 19 - 

	 	11.2	 All BsAb Improvements shall be (i) jointly owned by ABL Bio and
I-Mab (Oa: Oi) in the Rest of World as specified in Appendix 5; (ii) owned solely by ABL Bio in ABL Bio’s Territory; and (iii) owned solely by I-Mab in I-Mab’s Territory. The Parties will coordinate the preparation, filing, prosecution and maintenance of any patents covering any BsAb Improvement. All costs and expenses in relation to the prosecution,
settlement and compensation shall be (i) shared by ABL Bio and I-Mab (Oa: Oi) in the Rest of World as specified in Appendix 5; (ii) solely born by ABL Bio in ABL Bio’s Territory; and
(iii) solely born by I-Mab in I-Mab’s Territory. 

  

	 	11.3	 As between the Parties, all BsAb Technology (including BsAb Technology Improvements) and ABL Bio Parental
Antibody (including ABL Bio Parental Antibody Improvements) shall be solely owned by ABL Bio. As between the Parties, ABL Bio has the sole right for the preparation, filing, and maintenance of any patents covering any BsAb Technology (including BsAb
Technology Improvements) and ABL Bio Parental Antibody (including ABL Bio Parental Antibody Improvements). All costs and expenses incurred relation to the preparation, filing, and maintenance shall be solely born by ABL Bio. 

 

	 	11.4	 All I-Mab Parental Antibody (including
I-Mab Parental Antibody Improvements) shall be solely owned by I-Mab. I-Mab has the sole right for the preparation, filing, and
maintenance of any patents covering I-Mab Parental Antibody (including I-Mab Parental Antibody Improvements). All costs and expenses incurred relation to the
preparation, filing, and maintenance shall be solely born by I-Mab. 

  

	 	11.5	 During and after the Term, I-Mab will, and will cause its Affiliates
and representatives to, (i) cooperate fully in obtaining patent and other proprietary protection for any patentable or protectable BsAb Technology Improvements and ABL Bio Parental Antibody Improvements, all in the name of ABL Bio and at ABL
Bio’s cost and expense; and (ii) execute and deliver all requested applications, assignments and other documents, and take such other measures as ABL Bio reasonably requests, in order to perfect and enforce ABL Bio’s rights in BsAb
Technology Improvements and ABL Bio Parental Antibody Improvements. I-Mab appoints ABL Bio as its attorney to execute and deliver any such documents on behalf of I-Mab
and its Affiliates and representatives in the event I-Mab, its Affiliates or its representatives fail to do so. 

  

	 	11.6	 During and after the Term, ABL Bio will, and will cause its Affiliates and representatives to,
(i) cooperate fully in obtaining patents and other proprietary protections for any patentable or protectable I-Mab Parental Antibody Improvements, all in the name of
I-Mab and at I-Mab’s cost and expense; and (ii) execute and deliver all requested applications, assignments and other documents, and take such other measures
as I-Mab reasonably requests, in order to perfect and enforce I-Mab’s rights in I-Mab Parental Antibody Improvements. ABL
Bio appoints I-Mab as its attorney to execute and deliver any such documents on behalf of ABL Bio and its Affiliates and representatives in the event ABL Bio, its Affiliates or its representatives fail to do
so. 

  
 - 20 - 

	 	11.7	 Each Party shall be responsible for the maintenance of its own intellectual property rights during the Term of
this Agreement. 

  

	 	11.8	 In the event of the institution of any suit by a Third Party against a Party or its Affiliates for Patent Right
infringements involving the registration, development, manufacture, use, sale, distribution, or marketing of the Products, the Party being sued shall promptly inform the other Party in writing and shall take appropriate action to defend such suit at
its own expense; provided however that, if such Third Party action affects the BsAb Technology’s or ABL Bio Parental Antibody Technology’s freedom to operation, then ABL Bio shall have the first right, but not the obligation, to take over
and control the defense of such action; and if such Third Party action affects I-Mab Parental Antibody Technology’s freedom to operation, then I-Mab shall have the
first right, but not the obligation, to take over and control the defense of such action. The cost and expense sharing are pursuant to Sections 11.2, 11.3, and 11.4. ABL Bio and I-Mab
shall provide reasonable assistance to one another and reasonably cooperate in any such litigation at the other Party’s request without expense to the requesting Party. 

 

	 	11.9	 In the event I-Mab becomes aware of actual or threatened infringement
or validity attacks of BsAb Technology, ABL Bio Parental Antibody Patent Rights or ABL Bio Parental Antibody Know-How in I-Mab’s Territory, I-Mab shall promptly notify ABL Bio in writing of such actual or threatened activity or validity attacks. ABL Bio shall have the first right, but not the obligation, to bring an action against any infringement of
BsAb Technology, ABL Bio Parental Antibody Patent Rights or ABL Bio Parental Antibody Know-How. If ABL Bio elects to institute the enforcement action, it shall have full control over such enforcement action,
including settlement thereof. In any event, at ABL Bio’s request, I-Mab shall provide reasonable assistance and cooperation to ABL Bio in connection with any such proceeding, provided, however that all
reasonable third-party out of pocket costs shall be borne by ABL Bio and reimbursable to I-Mab upon written request. ABL Bio shall bear all of its costs and expenses of such enforcement actions and shall be
entitled to retain all monetary and non-monetary recoveries or settlements obtained as a result. In the event ABL Bio elects not to institute the enforcement action in accordance with this
Section 11.9, and I-Mab reasonably believes such infringement has a significant negative impact on the rights granted to its hereunder, I-Mab
shall, upon reasonable advance notice to ABL Bio, be entitled to institute enforcement actions to enjoin such infringement; provided, however, that (a) I-Mab shall keep ABL Bio informed of any such
proceedings in a timely manner, and (b) the settlement of any such proceedings instituted by I-Mab shall be subject to ABL Bio’s prior written approval, which shall not be unreasonably withheld or
delayed. ABL Bio shall use its best and good faith efforts to assist and cooperate with I-Mab and provide I-Mab with such assistance and information as may be reasonably
requested by I-Mab in respect of any such action; provided, however, that all reasonable third-party out of pocket costs with respect to such enforcement action shall be borne by
I-Mab and reimbursable to ABL Bio. I-Mab shall bear all of its costs and expenses of such enforcement actions and shall be entitled to retain all monetary and non-monetary recoveries or settlements obtained as a result. 

  

	 	11.10	 In the event ABL Bio becomes aware of actual or threatened infringement or validity attacks of I-Mab Parental Antibody Patent Right or I-Mab Parental Antibody Know-How in ABL Bio’s Territory, ABL Bio shall promptly notify I-Mab in writing of such actual or threatened activity or validity attacks. I-Mab shall have the first right, but not the obligation, to bring an action against any
infringement of I-Mab Parental Antibody Patent Right or I-Mab Parental Antibody Know-How. If
I-Mab elects to institute the enforcement action, it shall have full control over such enforcement action, including settlement thereof. In any event, at I-Mab’s
request, ABL Bio shall provide reasonable assistance and cooperation to I-Mab in connection with any such proceeding , provided, however that all reasonable third-party out of pocket costs shall be borne by I-Mab and reimbursable to ABL Bio upon written request. I-Mab shall bear all of its costs and expenses of such enforcement actions and shall be entitled to retain all monetary
and non-monetary recoveries or settlements obtained as a result. In the event that I-Mab elects not to institute the enforcement action in accordance with this
Section 11.10, and ABL Bio reasonably believes such infringement has a material negative impact on the rights granted to it hereunder, ABL Bio shall, upon reasonable advance notice to
I-Mab, be entitled to institute enforcement actions to enjoin such infringement in its own right upon reasonable advance notice to I-Mab; provided, however, that
(a) ABL Bio shall keep I-Mab informed of any such proceedings in a timely manner, and (b) the settlement of any such proceedings instituted by ABL Bio shall be subject to I-Mab’s prior written approval, which shall not be unreasonably withheld or delayed. I-Mab shall use its best and good faith efforts to assist and cooperate with ABL Bio
and provide ABL Bio with such assistance and information as may be reasonably requested by ABL Bio in respect of any such action; provided, however, that all reasonable third-party out of pocket costs with respect to such enforcement action shall be
borne by ABL Bio and reimbursable to I-Mab. ABL Bio shall bear all of its costs and expenses of such enforcement actions and shall be entitled to retain all monetary and
non-monetary recoveries or settlements obtained as a result. 

  
 - 21 - 

	 	11.11	 The Parties shall keep another informed of the status of their respective activities regarding any litigation
or settlement thereof concerning the Products. 

  

	 	11.12	 The Parties shall coordinate with each other for the assign, transfer, license or grant any of its rights in
BsAb Improvements in the Rest of the World. Neither party shall assign, transfer, license or grant any of its rights in BsAb Improvements in the Rest of the World to a third party without the consent of the other Party, such consent shall not be
unreasonably withheld. 

  

	12.	 Termination 

 

	 	12.1	 This Agreement shall continue for the Term, if not terminated earlier as described in this
Section 12. 

  

	 	12.2	 Either Party (the “Non-Breaching Party”) may, without
prejudice to any other remedies available to it at law or in equity, terminate this Agreement in its entirety in the event the other Party (the “Breaching Party”) has materially breached or defaulted in the performance of any of its
obligations hereunder and such default has continued for sixty (60) days after written notice thereof was provided to the Breaching Party by the Non-Breaching Party. Any such termination will become
effective at the end of such 60-day period unless the Breaching Party has cured any such breach or default prior to the expiration of such 60-day period. Notwithstanding
the foregoing, in the event and to the extent that any such breach is a payment breach, the applicable notice and cure period as provided above will be ten (10) Business Days. 

 

	 	12.3	 In the event that: 

  

	 	12.3.1	 I-Mab or any of its Affiliates (the “ABL Bio Challenging
Party”) (i) commence or participate in any action or proceeding (including any patent opposition or re-examination proceeding), or otherwise assert in writing any claim, challenging or denying the
validity of any of the BsAb Technology or ABL Bio Parental Antibody Patent Rights (each a “ABL Bio Technology Challenge”) or (ii) actively assist any other person or entity in bringing or prosecuting any ABL Bio
Technology Challenge, then ABL Bio has the right to terminate this Agreement immediately by giving notice to the ABL Bio Challenging Party (and, if the ABL Bio Challenging Party is not I-Mab, to give such
notice to I-Mab as well). 

  
 -22 - 

	 	12.3.2	 ABL Bio or any of its Affiliates (the “I-Mab Challenging
Party”) (i) commence or participate in any action or proceeding (including any patent opposition or re-examination proceeding), or otherwise assert in writing any claim, challenging or denying the
validity of any of the I-Mab Parental Antibody Patent Rights, or any claim thereof (each, a “I-Mab Patent Challenge”) or (ii) actively assist any
other person or entity in bringing or prosecuting any I-Mab Patent Challenge, then I-Mab has the right to terminate this Agreement immediately by giving notice to the I-Mab Challenging Party (and, if the I-Mab Challenging Party is not ABL Bio, to give such notice to ABL Bio as well). 

 

	 	12.4	 In the event that there is an early termination of this Agreement in accordance with Sections 12.2 or
12.3 after completion of Late Development and either Party continues the further development and commercialization of the Products in any Territory, the Party continuing the development and commercialization of the Product shall continue to
be obliged to pay to the other Party the royalty and the Out-License income sharing as described under Section 4 of this Agreement, provided that such rights have accrued hereunder
prior to the effective date of such termination. 

  

	 	12.5	 The following provisions will survive any expiration or termination of this Agreement for the period of time
specified therein, or if not specified, then they will survive indefinitely: Sections 1, 8, 10, and 13, and Sections 5.3, 7.1, 11, 12.4, 12,5 and 12.6. Termination of this Agreement will
not relieve the Parties of any liability and/or payment obligation that accrued hereunder prior to the effective date of such termination nor preclude either Party from pursuing all rights and remedies it may have hereunder or at law or in equity
with respect to any breach of this Agreement. The remedies provided in this are not exclusive of any other remedies a Party may have in law or equity. 

  

	 	12.6	 The Parties acknowledge and agree that in the event insurmountable technical difficulties and risk factors
(“Risk”) occurs to a Party and such Risk is not resolved by the Party within 90 days thereafter despite all reasonable efforts, the Party shall be entitled to terminate this Agreement by sending a written notice to the other Party.
After termination of this Agreement in accordance with this Section 12.6, the losses incurred to the Parties shall be borne by the Parties respectively, and the terminating Party will no longer have the right to continue
developing any Product. 

  

	13.	 Miscellaneous 

 

	 	13.1	 All disputes which arise in connection with this Agreement and its interpretation shall be settled in amicable
way between the Parties. If the dispute cannot be settled in friendly way, it will be settled by arbitration to be held in New York in conformity with the rules of International Chamber of Commerce (ICC). Such arbitration will be held in the English
language. The decision of the arbitrator will be final and binding on the Parties. 

  

	 	13.2	 This Agreement shall be construed, and the respective rights of the Parties determined, according to the Laws
of the State of New York, without regard to its choice of law principles. 

  

	 	13.3	 In the event that any legal proceeding is brought to enforce or interpret any of the provisions of this
Agreement, the prevailing Party shall be entitled to recover its reasonable attorney fees, court costs and expenses of litigation whether or not the action or proceeding results in a final judgment. 

  
 -23 - 

	 	13.4	 This Agreement may not be assigned or transferred by either Party, in whole or in part, whether voluntarily or
by operation of law, without the prior written consent of the other Party; provided that either Party my assign this Agreement, in whole or in part, to any of its Affiliates if such Party guarantees the performance of this Agreement by such
Affiliate; and provided further that ABL Bio and/or I-Mab may assign this Agreement to a successor to all or substantially all of its assets or business to which this Agreement relates, whether by merger, sale
of stock, sale of assets or other similar transaction. Any assignment in violation of this provision is void and without effect. This Agreement shall be binding upon and inure to the benefit of the Parties hereto, their permitted successors, legal
representatives and assigns. 

  

	 	13.5	 All notices must be in writing in English and sent to the address for the recipient set forth in this Agreement
or at such other address as the recipient may specify in writing under this procedure. 

  

					
		  	If to ABL Bio:	  	ABL Bio
		  		  	***
		  	            with a copy to:	  	***
			
		  	If to I-Mab:	  	I-MAB Biopharma Co., Ltd.
		  		  	***
		  	            with a copy to:	  	***

  

	 	13.6	 All notices must be given (a) by personal delivery, with receipt acknowledged; or (b) by prepaid
certified or registered mail, return receipt requested; or (c) by prepaid recognized express delivery service. Notices will be effective upon receipt or at a later date stated in the notice. If any provision of this Agreement is held to be
invalid, illegal or unenforceable in any respect, that provision shall be limited or eliminated to the minimum extent necessary so that this Agreement shall otherwise remain in full force and effect and enforceable. 

 

	 	13.7	 The headings used in this Agreement have been inserted for convenience of reference only and not define or
limit the provisions hereof. 

  

	 	13.8	 No waiver of any term or condition of this Agreement shall be effective unless set forth in this Agreement, all
rights and remedies available to a Party, whether under this Agreement or afforded by Law or otherwise, will be cumulative and not in the alternative to any other righty or remedies that may be available to such Party. 

 

	 	13.9	 This Agreement (including the exhibits and schedules hereto) constitutes the entire agreement between the
Parties hereto with respect to the subject matter hereof and supersedes all previous agreements and understandings between the Parties with respect to such subject matter, whether written or oral, including, but not limited to all proposals,
negotiation, conversations, letters of intent, memoranda of understanding or discussions, between the Parties relating to the subject matter of this Agreement and all past dealing or industry custom. 

  
 - 24 - 

	 	13.10	 This Agreement may be altered, amended, or changed only by a writing making specific reference to this
Agreement and the clause to be modified, which amendment is signed duly by authorized representatives of ABL Bio and I-Mab. 

 

	 	13.11	 Nothing in this Agreement shall be deemed to constitute the grant of any license or other right in either
Party, to or in respect of any product, trademark, confidential information, trade secret or other data or any other intellectual property of the other Party except as expressly set forth herein. 

 

	 	13.12	 None of the provisions of this Agreement shall be for the benefit of or enforceable by any Third Party,
including, but not limited to, any creditor of either Party. 

  

	 	13.13	 This Agreement shall be deemed to have been drafted jointly by both Parties; and ambiguities, if any, shall not
be construed against either Party, irrespective of which Party may have actually drafted the ambiguous provision. 

  

	 	13.14	 This Agreement may be executed in counterparts, each of which, when executed, shall be deemed an original and
all of which together shall constitute one and the same document. 

 [REMAINDER OF THE PAGE INTENTIONALLY LEFT BLANK] 

  
 - 25 - 

 IN WITNESS WHEREOF, I-Mab and ABL Bio, by
their duly authorized officers, have executed this Collaboration Agreement as of the Effective Date. 
  

			
	 ABL Bio
  

/s/ ABL Bio
	  	 I-Mab
  

/s/ I-Mab

  
 - 26 - 

 Appendix 1 

ABL Bio Parental Antibody and BsAb Technology Description and Patent Rights 

[***] 

  
 - 27 - 

 Appendix 2 

I-Mab Parental Antibody Description and Patent Rights 

[***] 

  
 - 28 - 

 Appendix 3 

Early Development Plan 

[***] 

  
 - 29 - 

 Appendix 4 

Late Development Plan 

[***] 

  
 - 30 - 

 Appendix 5 

IP Ownership, Costs Sharing, Income Sharing, Royalty Sharing, and 

Calculation Examples 

[***] 

  
 - 31 - 

 Appendix 6 

Press Release 

[***] 

  
 - 32 -EX-10.19

 Exhibit 10.19 

Contract Number: 
 Product Development Agreement of
TG103 Project Between I-Mab Biopharma (Shanghai) Co., Ltd. and CSPC Baike (Shangdong) Biopharmaceutical Co., Ltd. 

December 10th, 2018 

  
 1 

 This Intellectual Property Licensing and Product Development Agreement (“this Agreement”) is
signed by and between the following parties on December 10th, 2018: 
 I-Mab Biopharma (Shanghai) Co., Ltd.,
registered address: *** (“I-Mab Biopharma”); and 
 CSPC Baike (Shangdong) Biopharmaceutical
Co., Ltd., registered address: *** (hereinafter referred to as “CSPC Group”). 
 Each of I-Mab
Biopharma and CSPC Group may be hereinafter individually referred to as “one party”, “each party” or “the Parties” and collectively as “both parties”. 

WHEREAS, 
  

	1.	 I-Mab Biopharma is an innovative biopharmaceutical research and
development company in the fields of autoimmune diseases, oncology immune and immune-mediated inflammatory diseases, who owns the rights of regional development and commercialization of TG103 and related intellectual property rights in China.
I-Mab Biopharma is seeking strategic partners for product development and commercialization in China. 

  

	2.	 CSPC Group is one of the leading comprehensive pharmaceutical companies in China, with product pipeline in
innovative drugs and professional product marketing ability, who has synergy with I-Mab Biopharma’s development areas. 

Parties are willing to carry out strategic cooperation on TG103 products, and develop and commercialize TG103 products for the treatment of type
2 diabetes mellitus and all indications related to this product in the territory. 
 THEREFORE, the parties have reached the following agreements, which
shall be abided by both parties. 
  

	1.	 DEFINITIONS RELATED TO THIS AGREEMENT 

 

	1.1	 Affiliate: refers to: (1) Any company or business entity in which one party directly or indirectly
owns fifty percent (50%) or more of its shares; or (2) any company or business entity that directly or indirectly owns fifty percent (50%) or more shares of one party; or (3) any company or business entity directly or indirectly controlled
by the company or business entity as described in (1) or (2); to refer to any company or business entity, as described in (1), (2) and (3), as the “Affiliate” of a party, a relevant written notice shall be issued by the party to the
other party and inform the other party about the Affiliate in the notice. 

 Certificate of ownership of property rights
of I-Mab Biopharma and its Affiliates and TG103 Project can be found in Annex 3. 
  

	1.2	 Third-party: refers to parties other than (1) Party A and its Affiliates; and (2) Party B and
its Affiliates. 

  

	1.3	 TG103 product: refers to the long-acting recombinant GLP-l Fc
fusion protein injection (including related patents) developed by I-Mab Biopharma based on the technology of hyFc technology platform. 

  
 2 

 For the avoidance of doubt, the TG103 project is the same as the project underlying “Clinical
Approval of TG103 for Injection approved by the CDE in China with the approval number of 2018L02834”. The clinical approval and product structure and sequence of the project are shown in Annex 1. 

 

	1.4	 Patent: Each party’s patent applications or patents of TG103 and its related patents (including
divisional applications and acquired patent rights). 

  

	1.5	 Proprietary technology: refers to non-public technology and
other information owned by the parties, including but not limited to concepts, discoveries, data, designs, molecular formulas, R&D plans, test and detection designs, test and test results, processes, test records, and data of chemistry,
pharmacodynamics, toxicology, clinical, analytical and quality control, data analysis, reports and summaries. 

  

	1.6	 Genexine’s intellectual property: refers to the patented hyFc platform of Genexine, Inc., a
Korean company, and the patents related to the licensed products granted by Genexine, Inc. to I-Mab Biopharma to use and sublicense (details of Genexine’s intellectual property rights can be found in
Annex 2 of this Agreement). hyFc platform refers to that a Fc fragment of IgG4 fused with the amino acid sequence of the target protein as defined in the Chinese Patent No. 201410851771, where amino acids at the position of 231-240 on IgG4 are replaced by the CH2 domain of IgD, thereby forming a long-acting protein drug with a longer half-life than the current protein, and the fusion protein formed only has a FcRn
site without Fcy Rs binding sites, avoiding stimulating cell lysis and producing immunogenicity. This Fc structure of IgD/IgG4 is the hyFc platform. 

 

	1.7	 Licensed compound: refers to a long-acting recombinant GLP-l Fc fusion protein. The molecular structure
and sequence of the fusion protein are presented in the Annex I. 

  

	1.8	 Licensed intellectual property rights: refers to I-Mab
Biopharma’s patents and proprietary technologies related to the licensed compounds and licensed products. 

  

	1.9	 New intellectual property rights: refers to any improvement, enhancement, modification or change of the
patents and proprietary technology related to the development and production of the licensed compounds and licensed products after the date of this Agreement. 

 

	1.10	 Licensed products: refers to one or more pharmaceutical (including diagnostic) products, including or
containing (1) TG103, alone or in combination with one or more of any and all other forms of active ingredients, current and future formulations , dosage forms and dosages, and methods of administration; or (2) any fragment
(including antigen binding regions or sequences or portions), variations, improvements, modifications or derivatives thereof. 

  

	1.11	 Treatment field: refers to type 2 diabetes mellitus, including combination therapy with other
pharmaceuticals for type 2 diabetes mellitus and all potential indications of the product. 

  

	1.12	 Territory: refers to the People’s Republic of China, excluding Hong Kong, Macao and Taiwan.

  

	1.13	 BLA Approval/Market Approval: refers to the first-time marketing approval of the licensed product in the
treatment area in the territory obtained from the drug regulatory agency. 

  

	1.14	 Reasonable commercial efforts: refers to that the efforts and resources used in the development and
commercialization of the licensed products shall be consistent with the efforts and resources used by companies of similar size in the pharmaceutical industry during similar product development and commercialization phases. 

 

	1.15	 First commercial sale: refers to the first sale or consumption of a licensed product to a third party
for final use in the territory. 

  
 3 

	1.16	 Net sales revenue: refers to the total amount of invoices issued by CSPC Group and its Affiliates and sub-licensees to unrelated third parties for the sale of products in the applicable areas, after deducting the following deductions relating to the sale of products in the applicable areas (if included in the total
sales price of the products invoiced or directly paid or assumed by CSPC Group and its Affiliates and sub-licensees): (1) allowed discounts of trade, quantity and cash; (2) any discounts, refunds,
rebates, price adjustments or any other similar subsidies (excluding salesperson commissions) that in substance reduced the net sales prices, and are compliant with China’s Generally Accepted Accounting Principles and applicable jurisdiction
laws; (3) recycling and subsidy of licensed products; and (4) any value-added tax levied on licensed products. 

  

	2.	 PURPOSE AND APPROVAL OF THE AGREEMENT 

 

	2.1	 I-Mab Biopharma warrants to own the following rights and shall provide
proof for such ownership: 

  

	 	(1)	 Description of intellectual property rights owned by I-Mab Biopharma:
Fusion polypeptide containing glucagon-like peptide-1 and immunoglobulin hybrid Fc and its application; Patent Application Number CN2010101771.1 and CN2015800643.8 

 

	 	(2)	 Description of technology owned by I-Mab Biopharma: possession of
patented technology and technology secrets, the licensed products can be produced independently and effectively by the CMO company designated by I-Mab Biopharma. 

 

	2.2	 The purposes of this Agreement to be entered into by and between CSPC Group and
I-Mab Biopharma (Tianjin) Co., Ltd. are: 

  

	 	(1)	 The exclusive licensing of I-Mab Biopharma to CSPC Group for the use of
patented technology owned by I-Mab Biopharma; and 

  

	 	(2)	 Transfer of production technology (not inferior to the current technical level of this licensed compound) and
process to the CSPC Group and in coordination with the CSPC group for technical optimization. 

  

	2.3	 Subjecting to the terms and conditions of this Agreement, I-Mab
Biopharma grants CSPC Group in the territory the exclusive, sole, non-transferable, irrevocable and sub-licensable license of the intellectual property rights during the
valid term of this Agreement, so as to develop and commercialize the licensed compound(s) and licensed product(s) within the territory. 

  

	2.4	 The CSPC Group may grant sub-licenses in the territory, but prior
written consent of I-Mab Biopharma (I-Mab Biopharma shall not unreasonably refuse to agree) shall be the condition precedent for such
sub-licenses (except for sub-licnesing to the Affiliates of the CSPC Group), and shall be subject to the restrictions on the CSPC Group as well as the obligations the
CSPC Group under this Agreement. 

  

	2.5	 If, during the valid term of this Agreement, part or all of the licensed intellectual property rights become
invalid, and the invalidation is not due to the violation of the relevant statements, guarantees and commitments made by I-Mab Biopharma in this Agreement, this Agreement shall continue to be in force with
respect to any other valid intellectual property rights. In this case, during the valid term of this Agreement, the CSPC Group shall continue to be obliged to pay the fees agreed upon by both parties under Article 3 of this Agreement for the
licensing of intellectual property rights (including patents and proprietary technologies) under this Agreement. 

  
 4 

	3.	 PAYMENTS AND PAYMENT METHOD 

 

	3.1	 Upfront payment 

The upfront payment is RMB15.0 million (capital: RMB fifteen million yuan), and CSPC Group will pay the upfront payment within 30 (thirty)
days after the entry into force of this Agreement. The upfront payment will not be refunded for any reason except for the reasons specified in paragraph 7.3.1 of this Agreement. 

 

	3.2	 Developmental milestone payments 

 

	3.2.1	 CSPC Group will pay milestone payments to I-Mab Biopharma within 30
(thirty) days after the following milestones are achieved: 

  

					
	 Serial
No.
	  	 Milestone Event
	  	 Milestone Payment (Unit: RMB)

	1	  	Authorized development changes for clinical approval	  	RMB15 million (RMBfifteen million)
	2	  	Completion of production process transfer	  	RMB10 million (RMB ten million)
	3	  	Phase II clinical end point	  	RMB25 million yuan (RMB twenty-five million)
	4	  	Phase III clinical end point	  	RMB35 million (RMBthirty-five million)
	5	  	 BLA Approval / Market Approval
 Market
Approval
	  	RMB50 million yuan (RMBfifty million)

  

	3.2.2	 Determination of milestone event realization 

CSPC Group shall notify I-Mab Biopharma immediately when the above milestone events have been achieved.
If the CSPC Group fails to notify I-Mab Biopharma of the achievement of the milestone event, but I-Mab Biopharma has reason to believe that the milestone should be
achieved, I-Mab Biopharma may inform the CSPC Group in writing, and both parties shall immediately meet to discuss the matter about the realization of the milestone event. Disputes over the realization of
milestone events may be resolved by means of dispute resolution under this Agreement. 
  

	3.3	 Sales commission 

 

	3.3.1	 Percentage of sales commission 

Within the sales commission period, the CSPC Group will pay sales commission to I-Mab Biopharma in
accordance with the percentage of sales commission agreed in the following table on the basis of the annual net sales revenue of licensed products in the calendar year: 
  

							
	 Serial
No.
	  	 Annual Net Sales Revenue of Licensed Product(s) (Unit:
RMB)
	  	Percentage of Sales
Commission	 
	 1
	  	Less than RMB500 million (including this number)	  	 	5	% 
	 2
	  	RMB500 million to RMB1 billion (including these numbers)	  	 	8	% 
	 3
	  	RMB1 to RMB2.5 billion (including these numbers)	  	 	9	% 
	 4
	  	More than RMB2.5 billion	  	 	10	% 

  
 5 

	3.3.2	 The term of commission of the product shall be the following, whichever later: 

 

	 	(1)	 Later patent expiration date of licensed product patent application No. 201410851771.1 and 201580071643.8
(the ultimately authorized GLP-1’s claims part) in the territory; or 

  

	 	(2)	 Ten (10) years after the first commercial sale of licensed products in the territory.

  

	3.4	 Tax duties 

The above-mentioned upfront payment, milestone payments and sales commission paid/to be paid by CSPC Group do not include value added tax, and
the value-added tax shall be borne by CSPC Group. Other taxes shall be borne by both parties in accordance with the law. 
  

	3.5	 Invoice 

Within 30 (thirty) working days after the receipt of the upfront payment, milestone payment and sales commission payment, I-Mab Biopharma shall issue a special VAT invoice with a tax rate of 6% or the applicable tax rate in accordance with the laws at that time to the CSPC Group. The CSPC Group shall pay the corresponding tax to I-Mab Biopharma 30 (thirty) working days after receipt of the invoice. 
  

	3.6	 Accounting books and records 

 

	3.6.1	 The CSPC Group shall keep complete and appropriate accounting records and books, including financial receipts
and monthly and quarterly accounting statements showing the sales, deductions, net sales revenue and other quantities and descriptions of the licensed product it sells, in accordance with relevant laws and regulations of China.

  

	3.6.2	 The above accounting records and books shall be kept separately from all other records and books not related to
the licensed product and shall be subject to inspection by I-Mab Biopharma or its duly authorized representative or agent. 

 

	3.6.3	 The CSPC Group shall allow I-Mab Biopharma (or its representative) to
check, audit and inspect all account books, records, audit reports, documents and other matters related to the production and sale of the licensed product in a reasonable time at most once every year, and the expenses shall be borne by I-Mab Biopharma. The manner and time of the above-mentioned checking, auditing and inspection shall not adversely affect the operation of CSPC Group or the sales of the licensed and transferred products, and the
results of such checking, auditing and inspection shall be kept confidential. 

  

	4.	 RESEARCH AND DEVELOPMENT 

 

	4.1	 Obligations of CSPC Group 

 

	4.1.1	 General agreement: 

CSPC Group has the final decision on the development of licensed compounds and licensed products in the therapeutic field in the territory,
including related research and development, clinical trials and registration activities. 

  
 6 

	4.1.2	 Accountability: 

The CSPC Group shall make reasonable commercial efforts to develop licensed compounds and licensed products to commercialize them in the
territory as soon as possible. Such development should be carried out according to the research and development plan jointly determined by both parties. The CSPC Group shall make reasonable commercial efforts to implement the R&D plan in order
to obtain marketing license for the licensed products in the field of treatment in the territory as soon as possible. Any change to the R&D plan shall be discussed and agreed by the Joint Development Committee. 

 

	4.2	 Obligations of I-Mab Biopharma 

 

	4.2.1	 I-Mab Biopharma is not allowed to develop for itself or for others the
long-acting recombinant GLP-1 Fc fusion proteins and products with competitive mechanism at the same targets based on the technology of hyFc technology platform in the territory. 

 

	4.2.2	 In order to ensure the development of licensed products in the field of treatment in the territory, I-Mab Biopharma should continue to assist the CSPC Group in completing the pre-clinical study of the licensed products required by the Chinese drug approval departments, and
provide all the research records and data. 

  

	4.2.3	 I-Mab Biopharma shall make reasonable commercial efforts to assist in
the transfer of licensed products to the production technology of CSPC Group. The technical indicators of production technology transfer shall not be lower than the existing technical level. The plan and acceptance criteria of production technology
transfer are listed in Annex 5. 

  

	4.2.4	 I-Mab Biopharma shall make reasonable commercial efforts to assist or
guide the CSPC Group in continuous optimization of production process of the licensed product. 

  

	4.3	 Project leader: 

Within 30 (thirty) days from the date of signing this Agreement, each party shall appoint the corresponding project leader and shall notify the
other party in writing in time. Each party shall notify the other party in writing in time when replacing its project leader. The project leaders will be responsible for facilitating the communications and coordinating in actions between the parties
in accordance with the terms of this Agreement. 
  

	5.	 COMMERCIALIZATION 

 

	5.1	 General agreement: 

CSPC Group has the final decision on the commercializtion of the licensed compounds and licensed products in the therapeutic field in the
territory. 
  

	5.2	 Accountability: 

CSPC Group shall make reasonable commercial efforts to start the marketing and sales activities of the licensed products within a reasonable
time after obtaining the sales license from the governmental departments. 
  

	5.3	 Reporting: 

CSPC Group shall provide summary report of the commercialization activities of its licensed products for the preceding six-month period on semi-annual basis. 

  
 7 

	6.	 JOINT DEVELOPMENT COMMITTEE 

 

	6.1	 Both parties agree to establish a Joint Development Committee (JDC) to monitor and coordinate the actions of
the parties and promote communications and cooperation between the two parties. The JDC is specifically responsible for: (1) Supervising the progress of development activities; (2) Discussing the issues of safety, scientific and technical
issues arising from the development of licensed products; discussing and proposing solutions for any delays or overdue delays in the development protocol; and (3) Performing other appropriate functions and making other appropriate decisions in
accordance with the written consent of both parties. 

  

	6.2	 Composition of the JDC: The JDC consists of 4 (four) members, 2 (two) appointed by each Party. Members of the
JDC should have the appropriate technical capabilities, industry experience and knowledge. Within thirty (30) days from the date of signing this Agreement, each party shall appoint the initial members of the JDC and notify the other party in
writing in a timely manner. If one party replaces the appointed member(s) of the JDC, the other party shall be promptly notified in writing. The JDC has two co-chairs, one appointed by the CSPC Group and one
by I-Mab Biopharma. 

  

	6.3	 The duties of the Co-Chairs are responsible for convening and presiding
over the JDC meetings and preparing the minutes of the JDC meetings. 

  

	6.4	 JDC meetings: The JDC will decide for itself when to convene a JDC meeting, but at least once every quarter.
The JDC Meetings may be convened in the form of meetings by person, teleconferences or videoconferences, but at least one meeting by person shall be held in each calendar year. Each party shall bear the cost of its participation in the JDC meetings.
Members of each party who are not members of the JDC may be invited to participate in the JDC meetings as required. 

  

	7.	 INTELLECTUAL PROPERTY RIGHTS 

 

	7.1	 Background intellectual property rights 

 

	7.1.1	 The licensed intellectual property rights of I-Mab Biopharma,
Genexine’s intellectual property rights and all intellectual property rights of the CSPS Group on the effective date of this Agreement shall be owned by each party. I-Mab Biopharma is responsible for the
preparation, application, implementation and maintenance of the patents for TG103 product. Since the entry into force of this Agreement, all fees incurred in the Territory for the implementation and maintenance of the patents of TG103 product will
be paid by the CSPC Group to I-Mab Biopharma on the basis of invoices provided by I-Mab Biopharma. 

 

	7.1.2	 I-Mab Biopharma shall grant
sub-licensing of Genexine’s intellectual property rights to CSPC Group for the development of TG103 product. 

  

	7.2	 New intellectual property rights 

Both parties agree that in the term of this Agreement, both parties shall have the right to continuously improve and optimize the licensed
products or licensed compounds, including, but not limited to, process improvement, quality improvement, extension of the scope of application of the licensed products or licensed compounds, and extension of the mode of application of the licensed
products or licensed compounds. For the new intellectual property rights arising from the implementation of the above-mentioned improvements, the parties agree as follows: I-Mab Biopharma will grant the
license of its new intellectual property rights generated by the implementation of the above-mentioned improvements for exclusive and free use to the CSPC Group in the territory, and the CSPC Group is responsible for paying the application and
maintenance fees for the new patents in the territory; the new intellectual property rights generated by the implementation of the above-mentioned improvements by the CSPC Group belong to the CSPC Group. 

  
 8 

	7.3	 Claims and infringement 

 

	7.3.1	 I-Mab Biopharma shall guarantee that it has the complete rights to the
licensed TG103 project, including license, sub-license, patent application right and patent right. After the entry into force of this Agreement, it shall guarantee that the CSPC Group shall acquire and enjoy
the right of free implementation. If a patent authorization for the licensed compound is not obtained from China Intellectual Property Office, or if the CSPC Group fails to exercise its right of free implementation, the CSPC Group has the right to
unilaterally terminate/end this Agreement, or continue to license the product development of the compound, or implement this Agreement and perform all rights and obligations. In case the CSPC Group terminates this Agreement for the above reasons, it
may issue a Contract Termination Letter to I-Mab Biopharma by entrusted attorney. I-Mab Biopharma shall refund the full amount paid by the CSPC Group within 30 natural
days after receiving the Letter. 

  

	7.3.2	 If a third party submits a claim of any nature claiming that the licensed intellectual property rights used by
the CSPC Group infringe or may infringe upon its patent or other proprietary rights, or that there are facts that may lead to such claims, the CSPC Group shall notify I-Mab Biopharma immediately when it knows
such claims or facts. However, the CSPC Group shall not take any action related to such claims or infringements without obtaining the written consent of I-Mab Biopharma.
I-Mab Biopharma shall notify the CSPC Group within three calendar days whether it intends to defend against such claims. If I-Mab Biopharma chooses to make a defense, I-Mab Biopharma shall, in its own name or in the name of the CSPC Group (as the case may be), exclusively control the defense and bear the expenses, but the CSPC Group shall give all reasonable assistance to I-Mab Biopharma for this purpose. If I-Mab Biopharma chooses not to make a defense, the CSPC Group shall have exclusive control over the defense and bear the expenses by its
own, but I-Mab Biopharma shall give all reasonable assistance to CSPC Group for this purpose. 

  

	7.3.3	 If a third party submits any claim for the licensed intellectual property rights stated in Paragraph 7.3.1 and
the CSPC Group suffers any claim, loss or damage as a result of such claim, unless such claim, loss or damage is caused by the violation of the obligations of this Agreement by the CSPC Group or the failure for CSPC Group to use the licensed
intellectual property rights in accordance with the provisions of this Agreement, I-Mab Biopharma shall make compensation to the CSPC Group and bear the responsibility of making compensation with and bear the
related expenses for the CSPC Group. Notwithstanding the above provisions, the total amount of the liability of I-Mab Biopharma shall not exceed the sum of the following items: (1) the upfront payment
actually received by I-Mab Biopharma in accordance with the terms of this Agreement; (2) any milestone payments actually received by I-Mab Biopharma in accordance
with the terms of this Agreement; and (3) any other payments actually received by I-Mab Biopharma in accordance with the terms of this Agreement. 

 

	7.3.4	 If the CSPC Group learns any information about third party infringement or possible infringement of the
licensed intellectual property rights of I-Mab Biopharma, it shall immediately notify I-Mab Biopharma. However, the CSPC Group shall not take any action related to such
infringements without obtaining the prior consent of I-Mab Biopharma. I-Mab Biopharma shall consult with the CSPC Group within three working days after receiving the
notification from the CSPC Group to determine that one party shall take legal action and the other party shall give all reasonable assistance. In the meantime, if negotiations fail, the CSPC Group has the right to unilaterally take measures to
safeguard its rights. If either party takes legal action, the two parties may negotiate the share of expenses and the attribution of compensation. 

  
 9 

	7.3.5	 If I-Mab Biopharma decides not to take action under Paragraph 7.3.4
above, the CSPC Group may bring lawsuit against the infringing party at its own expense after obtaining written consent from I-Mab Biopharma, and I-Mab Biopharma shall
give all reasonable assistance as required by the CSPC Group. All compensation that may be obtained by the CSPC Group for taking action on third-party infringements is owned by the CSPC Group. Notwithstanding the above provisions, the CSPC Group
shall not reach compromise, settlement or agreement with any third party on the licensed intellectual property rights without the written consent of I-Mab Biopharma. 

 

	7.3.6	 If a third party makes claims of any nature concerning the new intellectual property rights, the CSPC Group
shall immediately notify I-Mab Biopharma of such claims or facts. The CSPC Group has the right to take any action related to such claims or infringements and to inform
I-Mab Biopharma in a timely manner. If the CSPC Group waives to take action or make defense, I-Mab Biopharma has the right to decide whether to take action or raise
defense in its own name, but the CSPC Group shall give all reasonable assistance to I-Mab Biopharma for this purpose. 

  

	7.3.7	 One of the parties to this Agreement shall not be liable for any special, incidental or indirect damages
suffered by the other party as a result of the contract, intellectual property infringement, breach of warranty or other agreements. 

  

	8.	 INFORMATION EXCHANGE 

Data sharing mechanism between the two parties: I-Mab Biopharma will coordinate with Genexine to share
clinical study protocols and data, all clinical trials protocols, trial data and conclusions with the CSPC Group in China and beyond, to support the global clinical development and commercialization of the licensed product(s). 

 

	9.	 REPRESENTATION AND WARRANTIES 

 

	9.1	 The parties hereby mutually represent and warrant that: (1) It is a validly existing entity under the
applicable laws of its jurisdiction; (2) It has the necessary authorization to complete the services under this Agreement, including but not limited to the approval of relevant government departments or other institutions, and it has sufficient
capacity, rights and powers to implement and deliver this Agreement and to fulfil its obligations under this Agreement; (3) This agreement, upon its conclusion, shall constitute a legally enforceable, valid and binding agreement; (4) No
violation of applicable laws and regulations occurred during the negotiation and facilitation of the signing of this Agreement by each party or its affiliated companies; (5) Each party warrants compliance and ensures that its affiliates that
may participate in this Agreement comply with applicable laws and regulations in the performance of this Agreement; (6) The execution of this Agreement by each party or its affiliated company shall not conflict with any obligations it may
assume to any other person or the rights and obligations under any other agreement it may sign; and (7) In case of becoming aware of any violation of this Term, the Party shall immediately notify the other party. If one party violates the
representations and warranties, the other party shall be compensated for the loss. 

  

	9.2	 To the knowledge of I-Mab Biopharma, there are no pending or potential
claims or investigations for the licensed intellectual property rights. To the knowledge of I-Mab Biopharma, the license under this Agreement does not violate the relevant legal provisions or the rights of any
third party. To the knowledge of I-Mab Biopharma, the production, use and sale of licensed products will not infringe upon the intellectual property rights of any third party in the territory.

  

	10.	 TERMINATION 

  

	10.1	 This Agreement shall come into force immediately upon signature by both parties and shall have full legal
effect during the validity of this Agreement unless terminated in advance in accordance with this Agreement, provided that such termination shall not affect: 

  

	 	(1)	 The rights and obligations already enjoyed and assumed by the parties on the date of termination; or

  
 10 

	 	(2)	 the continued existence and validity of the rights and obligations of the parties under the terms and
conditions intended to survive termination and the provisions necessary for the interpretation or execution of this Agreement. 

  

	10.2	 Unless otherwise provided in this Agreement, this Agreement may be terminated in the following circumstances,

  

	 	10.2.1	 Unless otherwise specified, if one party seriously violates this Agreement, the other party may terminate this
Agreement by giving notice to such effect. If such breach could be corrected, but the defaulting party fails to make such correction within 60 (sixty) days after receiving the notification, this Agreement may be terminated. 

 

	 	10.2.2	 In case the force majeure lasting for 6 (six) months or other events that render the purpose of this Agreement
unachievable cause the CSPC Group to stop the research, development, production and sale of the licensed products, and the parties fail to find a fair solution, either party may notify the other party to terminate this Agreement;

  

	10.2.3	 If a party becomes bankrupt or insolvent, or is subject to liquidation or dissolution procedures or
arrangements, or ceases to operate, or is unable to pay the debts due, the other party may terminate this Agreement by giving notice; 

  

	10.2.4	 If, for the reasons of the CSPC Group, the CSPC Group fails to obtain the approval or registration from the
regulatory authority required to sell the Licensed Products in the territory in accordance with the business plan and timetable approved from time to time by its board of directors, or the CSPC Group ceases to engage in the licensed product
development or product registration in accordance with the written resolution of its board of directors, I-Mab Biopharma may terminate this Agreement by issuing a notice to the CSPC Group.

  

	10.3	 Upon the termination/ending of this Agreement for any reason, the CSPC Group shall immediately stop using the
licensed intellectual property rights provided by I-Mab Biopharma and stop producing the licensed products. CSPC Group shall promptly transfer to I-Mab Biopharma all
relevant data, information, cell lines, production processes and clinical samples of the licensed compounds and licensed products owned by the CSPC Group. 

  

	10.4	 Payment by the CSPC Group shall be suspended if this Agreement is terminated/ended by Clause 10.2.

  

	10.5	 CSPC Group shall return all the licensed intellectual property rights to
I-Mab Biopharma upon the early termination of this Agreement, including improved technology and technical documents related to the licensed intellectual property rights provided by I-Mab Biopharma that are recorded in any material form (including but not limited to any written records). CSPC Group, on behalf of itself and its employees, agrees that, at the time of termination or expiration of
this Agreement and beyond, copies of the licensed intellectual property rights in any form of materials or technical documents related to the licensed intellectual property rights shall not be made or retained, except for the purpose of archival
retention. 

  

	10.6	 Within 6 months after the signing of the Agreement, I-Mab Biopharma
will solve all intellectual property issues stated in Annex 6. Otherwise, I-Mab Biopharma will be deemed to have violated the agreements in Clause 7.3.1, and the CSPC Group has not obtained and enjoyed the
right of free implementation. The CSPC Group will have the right to terminate this Agreement. I-Mab Biopharma will assume the liability for breach of contract within 30 days after receipt of the termination
document in accordance with the agreements of Clause 7.3.1 by refunding the contractual amount of money that CSPC Group has paid. CSPC Group shall return all the licensed intellectual property rights to I-Mab
Biopharma, including improved technology and technical documents related to the licensed intellectual property rights provided by I-Mab Biopharma that are recorded in any material form (including but not
limited to any written records). 

  
 11 

	11.	 FORCE MAJEURE 

 

	11.1	 Force majeure event means any event that the Parties could not be expected to foresee, or, even that is
predictable, but unavoidable, that is entirely beyond the control of the Parties, and that prevents the obligations of the Agreement from being performed fully or partially by either Party. Such incidents include, but are not limited to, stoppages,
explosions, accidents, acts of natural disasters or public enemies, fires, floods, accidents, war riots, rebellions and any other similar probable events. 

  

	11.2	 In the event of force majeure, which prevents both parties from fulfilling any contractual obligations under
this Agreement, such contractual obligations shall be suspended during the period of delay in performance due to force majeure, and the time of performance of such contractual obligations shall automatically be extended to the time equivalent to the
suspension of such events without penalty. 

  

	11.3	 The party subject to force majeure shall notify the other party within 15 (fifteen) days of the occurrence of
the event concerned and provide the other party with an effective proof of the occurrence of force majeure. Within a reasonable period thereafter, the party subject to force majeure shall provide the other party with evidence of the occurrence of
force majeure issued by the relevant agency. The party subject to force majeure shall also make every reasonable effort to reduce the impact of such force majeure. 

 

	11.4	 After occurrence of the event of force majeure, both parties shall consult immediately to agree on a fair
solution (which may include early termination or extension of the term of this Agreement) and shall make every reasonable effort to reduce the consequences of such force majeure. 

 

	12.	 CONFIDENTIALITY AND PUBLICITY 

 

	12.1	 Confidential information. 

Confidential Information means all information and materials disclosed by one party or on behalf of the party or its affiliates or their
related persons (“Disclosing Party”) to the other party or its affiliates or their related persons (“Recipient”). Confidential information includes all the contents agreed upon in this Agreement, the existence, terms and purposes
of this Agreement, the nature of any dispute, the results of any arbitration proceedings arising out of or relating to this Agreement, and all information and materials involved in the implementation of this Agreement, including but not limited to
the nature of the project, test contents and progress, samples, programs, skills, amounts of money, materials, information, products, plans, technologies, data, experiments, market data, marketing, finance, sources of supply, business information,
business plans, forecasts, structures, concepts, methods, methodologies, procedures, experiments, models, tests, original atlas, photographs, proprietary skills, technical know-how, inventions, patent
applications, patent applications and any other documents and information, or information concerning third parties that are under the obligation of confidentiality of the Disclosing Party, whether the information is disclosed by the Disclosing Party
to the Recipient in writing, orally or otherwise. 

  
 12 

	12.2	 Confidentiality obligations. 

Unless otherwise provided in this Agreement, the Recipient shall, and shall ensure that its relevant personnel, (1) keep confidential of
the confidential information during the term of this Agreement, and this obligation of confidentiality shall remain valid after the expiration or termination or ending of this Agreement until the confidential information is legally disclosed or the
Disclosing Party notifies the Recipient in writing that it is not bound by this obligation of confidentiality; (2) not use the confidential information except for the purpose of fulfilling this Agreement; (3) not disclose the confidential
information to any third party, except for (1) those persons who need to know the service-related confidential information, provided that the Recipient shall be obliged to oblige the persons concerned to abide by the Agreement and bear
liability for the violation of this confidentiality obligation by the persons concerned; and (2) inspection, disclosure or other activities required by government agencies, judicial procedures (including, but not limited to, the extent to which
litigation, arbitration or responding, arbitration defenses are reasonably necessary), securities exchanges or relevant legal requirements 

To the extent permitted by law, the Recipient shall promptly notify the Disclosing Party in writing, and through reasonable efforts to ensure
that the confidential information is treated confidentially, and cooperate with the Disclosing Party to take reasonable measures to minimize the confidential information that may be disclosed, but the scope of the above disclosure shall be
controlled within the necessary limits. The Recipient agrees to take any feasible measures to protect the confidentiality of confidential information to a level not less than that of its own confidential content or content of the same nature, and to
avoid unauthorized disclosure and use. The obligations under this Clause 12.2 shall continue to be performed after the termination or ending or expiration of this Agreement. Notwithstanding the foregoing, the existence of this Agreement and its non-technical terms may be disclosed in a confidential manner as a result of potential financing or acquisition. 
  

	12.3	 Exception to confidentiality. 

The obligations provided under Clause 12.2 do not apply to the following circumstances: (1) Confidential information is public knowledge
or the confidential information that is not publicly known as a result of the fault or breach of contract of the Recipient or its related personnel; (2) the Recipient can provide evidence to prove that it or its relevant personnel have legally
known the confidential information before the Disclosing Party disclose it to the Recipient; (3) the Recipient may provide evidence that it or its related personnel legally acquired such confidential information from a third party that has no
obligation to keep confidentiality to the Disclosing Party or its associated personnel, in a manner of not violating the confidentiality obligations of this Agreement; or (4) the Recipient can provide evidence that the it or its related
personnel has not relied on the confidential information and that the confidential information has not been independently developed by the Recipient in violation of this Agreement. 

 

	12.4	 Return of confidential information. 

Within 30 days after the termination or ending or expiration of this Agreement, the Recipient shall, at the written request of the Disclosing
Party, return all Confidential Information to the Disclosing Party (including any form of photocopy or reproduction), or immediately destroy it in its entirety, and shall provide the Disclosing Party with proof of its destruction of the information
and materials; However, where prior written consent of the Disclosing Party is obtained and used for the sole purpose of this Agreement and the obligation of confidentiality is assumed, the Recipient has the right to retain the corresponding
confidential information for the purpose of legal archiving . 
  

	12.5	 Publishing. 

The parties hereto shall and shall ensure that their relevant personnel strictly keep confidential the confidential information under this
Agreement. Before obtaining the written permission of the other party, neither party shall disclose or permit any third party to contact, know, learn, utilize or use any of the confidential information for any purpose or in any way, nor shall any
content of confidential information under this Agreement be published in articles or otherwise made public. 

  
 13 

	12.6	 Publicity. 

Without the prior written consent of the other party, neither party shall, and ensure that its relevant personnel will not, use the name,
trademark, trade name, symbol or logo of the other party in any advertisement or propaganda materials. 
  

	13.	 COMPENSATION 

  

	13.1	 One Party hereto shall protect, compensate and ensure that the other Party and its affiliated companies and its
and their directors, personnel, employees, agents, subcontractors and consultants, as well as legal, financial, accounting, consultants and other consulting parties who need to know the information, are not harmed and exempt from liability and
damages (including reasonable attorney’s fees) arising from third party claims, requirements, lawsuits or procedures. 

  

	13.2	 In any case, the liability for damages suffered by either party to this Agreement for the other party does not
include indirect loss, incidental loss and expected loss of profits. 

  

	14.	 APPLICATION OF LAW AND DISPUTE RESOLUTION 

 

	14.1	 The validity, interpretation, performance and other related matters of this Agreement shall be governed by the
laws of the People’s Republic of China and the principles of conflict of laws shall not invoke. 

  

	14.2	 The parties to this Agreement shall negotiate in good faith to resolve any disputes arising from or related to
this Agreement. The negotiation shall begin immediately after one party submits a request for negotiation to the other party. If the dispute cannot be resolved within 30 days from the date of submission of the request for consultation, either party
may submit the dispute to the Beijing Branch of the China International Economic and Trade Arbitration Commission (CIETAC) for arbitration in accordance with the CIETAC Arbitration Rules in force at the time of submission. The place of arbitration
is Beijing. The official language of arbitration is Chinese. The arbitral tribunal shall consist of an arbitrator appointed by CIETAC. The arbitration procedure is confidential, and the arbitrator may issue appropriate protection orders to protect
the confidential information of the parties. The arbitral award shall be final and binding upon the parties. The parties may apply to the court of competent jurisdiction for enforcement of the arbitral award. 

 

	15.	 INDEPENDENT CONTRACTORS 

Both parties are independent contractors, and no provision of this Agreement shall, for any reason, make one party an agent, partner, legal
representative, principal or employee of the other party. Except as otherwise expressly provided in this Agreement, neither party shall have the right to bind the other party. 

 

	16.	 THE TERM OF THIS AGREEMENT AND THE RIGHTS OF BOTH PARTIES AFTER THE EXPIRATION OF THIS AGREEMENT:

 The term of this Agreement begins on the date of signature and expires at the end of the product commission period.
After the expiration of this Agreement, both parties shall continue to abide by the confidentiality obligations stipulated in Article 12 of this Agreement. In the event that the CSPC Group fully fulfills its obligations under this Agreement, after
the expiration of this Agreement, the CSPC Group will fully enjoy the full ownership of the Licensed Products and/or Licensed Compounds in the territory, including but not limited to technical data, research results, sales revenue, etc., I-Mab Biopharma will no longer enjoy the relevant sales commission. 

  
 14 

	17.	 OTHER TERMS 

  

	17.1	 Transfer. 

This Agreement shall be binding on both parties and their respective successors and permitted transferees. 

 

	17.2	 Notice 

  

	 	17.2.1	 Any notice under this Agreement shall be in writing and shall be deemed to have been delivered upon
receipt of the notice by the intended recipient of the notice. The means of proof of receipt include: (1) if the notice is delivered by hand, the recipient’s written receipt or proof of the delivery personnel, confirming that the recipient
has received or refused to receive the relevant notice; (2) if delivered by registered mail or express mail (receipt thereof shall be requested) or by internationally renowned express delivery, a signed receipt or other written proof of
delivery; or (3) if sent by e-mail, the electronic certification material of the sent e-mail. 

 

	17.2.2	 Mailing address and contact person 

 

	 	I-Mab	 Biopharma: 

  

			
	Address	  	***
	Postal Code	  	***
	Contact Person	  	***
	E-mail Address	  	***

  

	 	CSPC	 Group: 

  

			
	Address	  	***
	Postal Code	  	***
	Contact Person	  	***
	E-mail Address	  	***

  

	17.2.3	 Any change in the address and contact person of either party shall be notified to the other party in a timely
manner. 

  

	17.3	 Complete contract terms. This Agreement covers all the agreements between the Parties concerning the subject
matter of this Agreement and supersedes all oral and written agreements, contracts, understandings, discussions, negotiations and notifications made by the Parties before signing this Agreement. 

  
 15 

	17.4	 Amendments. No modification or waiver of any of the provisions contained in this Agreement or any other form of
amendment to this Agreement shall be binding upon the Parties unless expressly specified and signed by both parties in writing. 

  

	17.5	 No waiver. Any party’s waiver of its rights to seek relief against breach of any provision of this
Agreement by the other party shall not constitute the waiver of its rights to seek relief against breach of any other provision of this Agreement by the other party. The failure or delay of either party in exercising any right under this Agreement
does not constitute a waiver of that right or other rights, nor does it adversely affect such right or any other rights. The waiver of any right shall be made in writing by the waiver, otherwise it has no legal effect. 

 

	17.6	 Severability If any provision of this Agreement is deemed to be invalid, illegal or unenforceable, then

  

	(1)	 The term will be replaced by an effective and enforceable clause that maximizes the intentions of both parties;
and 

  

	(2)	 All other terms of this Agreement remain in full force and effect. 

 

	17.7	 Annexes to the Agreement 

The Annexes to this Agreement are an integral part of this Agreement and have the same legal effect as the body of this Agreement. 

 

	17.8	 This Agreement shall come into force on the date of signature and seal by the parties. This Agreement is in
four copies, each party holds two copies and each copy shall has the same legal force. 

 Relevant Annexes: 

Annex 1 Molecular Structure and Sequence of TG103 
 Annex 2 List
of Patents Licensed to CSPC Group Included in This Agreement 
 Annex 3 Certificate of Ownership Issued by the Relevant Parties of Licensed Products 

Annex 4 Notice of Change of Applicant/Patentee 
 Annex 5 Technical
Indicators for Transfer of Production Technology of TG103 Products 
 Annex 6 List of Intellectual Property Issues Needed to be Solved by I-Mab Biopharma within 6 Months of Contract Signing 
 (The remainder of this page is intentionally left blank)

  
 16 

 (SIGNATURE PAGE ) 
 Party A 

CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. (seal) 
 /s/
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. 
 Party B 

I-Mab Biopharma (Shanghai) Co., Ltd. (seal) 

/s/ I-Mab Biopharma (Shanghai) Co., Ltd. 

  
 17 

 Annex 1 Molecular Structure and Sequence of TG103 

[***] 

  
 18 

 Annex 2 List of Patents Licensed to CSPC Group Included in This Agreement 

[***] 

  
 19 

 Annex 3 Certificate of Ownership Issued by the Relevant Parties of Licensed Products 

[***] 

  
 20 

 Annex 4 Notice of Change of Applicant/Patentee 

[***] 

  
 21 

 Annex 5 Technical Indicators for Transfer of Production Technology of TG103 Products 

[***] 

  
 22 

 Annex 6 List of Intellectual Property Issues Needed to be Solved by I-Mab Biopharma within 6 Months of Contract Signing 
 [***] 

  
 23

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00301-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00301-of-00352.parquet"}]]